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ABSTRACT 
 
Alpha-amino-3-hydroxy-5-methyl-4-isoxazole propionate (AMPA) receptors are glutamate-
gated cation channels and mediators of fast excitatory neurotransmission in the mammalian 
central nervous system. Trafficking and functional regulation of AMPA receptors GluA1-4 is 
carried out through numerous intracellular protein interactions and post-translational 
modifications. The aim of this thesis work was to study the selective interaction between 
AMPA receptor subunit GluA1 and synapse-associated protein 97 (SAP97), a protein 
scaffold belonging to the protein family of membrane associated guanylate kinase homologs. 
The interaction between SAP97 and GluA1 has been implicated in AMPA receptor 
trafficking, neuronal development and synaptic plasticity, while disturbances in normal levels 
of both GluA1 and SAP97 have been linked to neuropathologies such as Alzheimer’s disease 
and schizophrenia. 
 
In the present study, a combination of biochemical and structural work was employed to gain 
detailed information on the selective interaction of GluA1 with SAP97 identifying molecular 
determinants involved in and regulating the interaction. X-ray crystallization screens of the 
second PDZ domain of SAP97 (SAP97PDZ2) yielded well-diffracting crystals both for the apo 
and ligand bound form. The solved crystal structure of the SAP97PDZ2-GluA1 peptide 
complex conformed to a conventional class I PDZ interaction with hydrogen bonds forming 
between the carboxylate group of the ultimate C-terminal residue of the peptide and main 
chain nitrogens in the carboxylate binding loop of the PDZ domain, and a hydrogen bond 
between the antepenultimate residue of the peptide and a conserved histidine in the αB helix 
lining the peptide binding groove. Beside these typical PDZ interactions, as a novel finding 
we observed contacts within the PDZ domain reorganizing upon peptide binding leading to a 
slight opening of the peptide binding groove facilitating better accommodation of the ligand.  
 
In vitro binding analysis of isolated PDZ domains and short GluA1 peptides showed that, in 
addition to the prototypic PDZ interaction, a C-terminal cysteine, C893 located upstream 
from the short PDZ binding motif on GluA1 participated in the interaction through a disulfide 
bond formed with cysteine C378 of SAP97 under in vitro conditions. Streptavidin pull-down 
experiments with full-length molecules expressed in cultured cells showed that the C893S 
mutation leads to a substantial reduction in binding of GluA1 to SAP97, confirming the 
involvement of C893 in the regulation of the interaction in live cells. Reactive cysteines, like 
C893, can in addition to disulfide bonds participate in other thiol modifications. In our work 
we constructed several deletion and cysteine replacement mutants of GluA1 and tested their 
sensitivity to S-nitrosylating agents nitrosoglutathione and nitrosocysteine. Out of the three 
C-terminal cysteine residues in GluA1, we identified C893 as the sole cysteine residue 
sensitive to a post-translational modification by NO. Furthermore, we found evidence of a 
physical link between GluA1 and the NO generating neuronal enzyme nitric oxide synthase 
nNOS via SAP97. 
 
The results of the present study provide, for the first time, detailed structural information on 
the interaction between GluA1 AMPA receptor and SAP97. In addition to a canonical PDZ 
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interaction, the association with SAP97 involves a reactive cysteine residue, C893, in GluA1 
C-terminal tail, a potential regulatory target for nitric oxide and oxidative conditions.  
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1. REVIEW OF THE LITERATURE 
 
1.1 The synapse 
 
The nervous system is a complex network of billions of neurons that effectively communicate 
with each other through specialized connections called synapses. The synapse is a structure 
consisting of parts from both the information-transmitting presynaptic neuron and the 
receiving postsynaptic neuron. Most of the synapses are chemical synapses in which the 
information is transmitted by neurotransmitters released from synaptic vesicles in the 
presynaptic nerve ending. The neurotransmitters diffuse over the narrow synaptic cleft and 
bind to receptors on the postsynaptic membrane. The response of the postsynaptic cell can be 
either inhibitory or excitatory. Excitatory responses increase the probability of the 
postsynaptic cell to produce an action potential while inhibitory responses decrease the 
probability for an action potential in the receiving cell. Most excitatory synapses are 
glutamatergic (i.e., use glutamate as neurotransmitter) and are located on dendritic spines, 
specialized membranous protrusions on the postsynaptic cell (Figure 1). 
 
Figure 1. Excitatory synapse.  
 
 
A rapid, efficient information transfer between adjacent neurons require perfect alignment 
between the active zone, a presynaptic area from where transmitter-filled vesicles fuse with 
the plasma membrane, and the postsynaptic density (PSD), an electron dense specialization 
containing glutamate receptors and channels, cytoskeletal proteins, signaling molecules and 
scaffolding proteins, residing on the postsynaptic neuron (Okabe, 2007; Sheng and 
Hoogenraad, 2007). 
 
In addition to postsynaptic receptors, among principal building blocks of synapses are the 
membrane-associated guanylate kinase (MAGUK) homologs. MAGUKs are scaffolding 
proteins bringing cytoskeletal proteins, receptors, signaling molecules, and adhesion 
molecules together at specific locations facilitating efficient cell-to-cell communication. 
Early in evolution, before the emergence of multicellular organisms, MAGUK containing 
complexes presumably acted as sensors of their environment and regulated exo- and 
endocytosis. With the evolution of metazoans the complexes formed by MAGUKs took on 
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more specialized functions such as the cell-to-cell contacts of neuronal synapses (de Mendoza 
et al., 2010; Zheng et al., 2011).  
 
This literature review will focus on synapse-associated protein 97 (SAP97), a MAGUK 
protein with several important roles in the development and plasticity of synapses, as well as 
its major interactor and an important mediator of excitatory neurotransmission in the central 
nervous system (CNS), the alpha-amino-3-hydroxy-5-methyl-4-isoxazole propionate 
(AMPA) glutamate receptor GluA1. 
 
1.2. Glutamate receptors 
 
Glutamate is the principal excitatory neurotransmitter in the mammalian CNS (Robinson and 
Coyle, 1987). The physiological effects of glutamate are mediated by various types of 
glutamate receptors expressed predominantly in the brain. Glutamate receptors are divided 
into two categories depending on how they convey their effect on the target cell upon ligand 
binding. Metabotropic glutamate receptors (mGluR) are G-protein coupled proteins that act 
through second messengers in the target cells conferring slow responses (see for review Conn 
and Pin, 1997), while ionotropic glutamate receptors (iGluR) are responsible for fast-acting 
neurotransmission exerting their effects via cations flowing through the ion channel pore 
once the ligand has bound. The iGluRs can be further divided into subclasses based on 
structural homology and their pharmacological preference for the non-native agonists AMPA, 
N-methyl-D-aspartate (NMDA) and kainate. In addition to AMPA-, NMDA- and kainate 
receptors, there is a fourth subclass, the δ-receptor, which shares structural homology, but 
does not yet have any identified agonist (Traynelis et al., 2010). Each subclass consists of 
several subunits (Figure 2). The nomenclature of iGluRs recommended by the International 
Union of Pharmacology Committee on Receptor Nomenclature and Drug Classification (NC-
IUPHAR) is presented in Table 1 (Palmer et al., 2005; Collingridge et al., 2009; Traynelis et 
al., 2010). The three major ionotropic glutamate receptor subclasses all have distinct roles in 
the CNS: AMPA receptors are the primary mediators of fast synaptic transmission (Jonas and 
Sakmann, 1992), NMDA receptors are involved in the induction of synaptic plasticity, and 
kainate receptors, are involved in modulation of neuronal function in less-well characterized 
ways (Traynelis et al., 2010). Most AMPA and NMDA receptors reside in the postsynaptic 
membrane, whereas kainate receptors localize also to presynaptic sites, where they regulate 
both inhibitory and excitatory transmitter release (Lerma, 2006; Pinheiro and Mulle; 2008; 
Jane et al., 2009; Traynelis et al., 2010; Contractor et al., 2011). In the following chapters, 
structural features of AMPA receptors will be discussed, but all iGluR subclasses show 
similarity at the level of amino acid sequence, domain organization, tetrameric assembly and 
three-dimensional structure. 
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Figure 2. Ionotropic glutamate receptor classification.  
 
 
 
Table 1. Harmonized nomenclature for ionotropic glutamate receptors recommended by NC-IUPHAR. 
 
  
12 
 
1.2.1. AMPA receptors and their structure 
Functional AMPA receptors are tetrameric integral membrane proteins composed of four 
subunits GluA1, GluA2, GluA3 or GluA4 forming either homomeric (consisting of identical 
subunits) or heteromeric (consisting of two or more subunit types) ion channels. Each of the 
approximately 900 amino acids long subunits have a modular structure consisting of an 
extracellular N-terminal domain (NTD), an extracellular ligand-binding domain (LBD), a 
transmembrane domain (TMD) and an intracellular C-terminal domain (CTD) (Figure 3). 
While the NTD, LBD and TMD are highly conserved amongst the different subunits, the 
CTDs are more varied and thus likely contributing to subunit-dependent functional 
differences. X-ray structures of near full-length AMPA receptor tetramers comprising the 
NTD, LBD and TMD have been obtained, representing different activity states, for both 
homomeric (Sobolevsky et al., 2009; Dürr et al., 2014; Chen et al., 2014) and heteromeric 
(Herguedas et al., 2016) AMPA receptors. The structural domains of AMPA receptors are 
discussed in the next chapters. 
 
Figure 3. AMPA receptor topology and structure. A schematic representation of an AMPA receptor subunit 
shown in the middle. Functional AMPA receptors are either homomeric, comprised of four identical subunits 
(shown on the left side), or heteromeric comprised of four differing subunits (shown on the right side). The 
homomeric GluA2 receptor (ProteinDataBank [pdb] coordinate 4UQJ) and heteromeric GluA2/3 receptor (pdb 
coordinates 5FWY [top view], 5IDE [side view]) are drawn with PyMol. 
 
 
1.2.1.1. The N-terminal domain 
AMPA receptors contain a large, approximately 400 residue long, extracellular domain 
homologous to the LBD of mGluRs and bacterial amino acid binding proteins (O'Hara et al., 
1993). The NTDs of AMPA receptors have no known ligands and the function of the NTD is 
largely unknown. NTDs are not obligatory receptor modules, since functional homomeric 
AMPA receptors form even in the absence of the NTD (Pasternack et al., 2002). Isolated 
NTDs form dimers in solution and have been suggested to play a role in the initial steps of 
subtype-specific receptor assembly (Kuusinen et al., 1999; Leuschner and Hoch 1999; 
Ayalon and Stern-Bach 2001; Ayalon et al., 2005; Matsuda et al., 2005; Gan et al., 2015). 
Crystal structures show that the NTD dimer is comprised of two clamshell-like structures, 
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each composed of an upper lobe and a lower lobe separated by a cleft. Residues in both the 
lower and upper lobe participate in the initial NTD dimer assembly, whereafter the dimer 
pairs form a tetramer through interactions between the lower lobes (Clayton et al., 2009; Jin 
et al., 2009; Yao et al., 2011; Kumar and Mayer; 2013). Although the NTDs of AMPA 
receptors have no known ligands, the dimeric NTDs are positioned with their clefts facing 
outwards to opposite directions, suggestive of a role as functional ligand-binding units 
(Krieger et al., 2015; Herguedas et al., 2016). While the homomeric GluA2 receptors adopt 
an elongated structure resembling the letter Y (Sobolevsky et al., 2009), the heteromeric 
GluA2/3 receptor adopts a compressed structure similar to the structure of the obligatory 
homomeric NMDA receptor GluAN1/N2B (Karakas and Furukawa, 2014; Herguedas et al., 
2016). The differences derive from the NTD assembly. In heteromeric GluA2/3 and GluA2/4 
the NTDs from the four subunits alternate around a central axis to create, when viewed from 
the top, a circular (O-shaped) structure differing from the loose zigzagging (N-shaped) 
arrangement seen in GluA2 homomers. The NTDs in heteromeric AMPA receptors are 
situated closer to the LBDs than the NTDs of homomeric receptors, thus giving the receptor a 
more compact structure. Simulations suggest that the receptor can alternate between the “O” 
and “N” states, which thus represent two allosteric conformations. Crystal structures of 
heteromeric GluA2/3 and GluA2/4 also indicate that structures in the lower lobe of NTDs 
may act as key determinants for subunit-selective receptor heteromerization (Herguedas et 
al., 2016). 
 
1.2.1.2 The ligand-binding domain 
Two approximately 150 residues long extracellular segments S1 and S2 separated by 
transmembrane helices 1-3 (M1-M3) (Stern-Bach et al., 1994) form the LBD of AMPA 
receptors. Like the NTDs, the LBDs form a clamshell-like structure with two distinct lobes. 
The agonist binds in a crevice between the lobes and induces a closure of the clamshell 
(Armstrong et al., 1998, 2000). The LBDs form a back-to-back dimer through contacts 
mediated by the upper lobes (Sobolevsky et al., 2009; Kumar and Mayer, 2013). The lower 
lobes of the dimer are in contact with the transmembrane segments M1 and M3, which flank 
the channel pore, and when the agonist binds, the resulting closure of the binding site cleft 
leads to an upward and lateral movement of the lower lobes, which pulls the receptor channel 
open. The resulting structure (binding site closed, channel open) is very unstable and is 
rearranged in a millisecond timescale into an more stable, desensitized state (binding site 
closed, channel closed) by disruption of the dimer interface formed by LBD upper lobes 
(Armstrong et al., 2000; Traynelis et al., 2010; Meyerson et al., 2014) (Figure 4).  
 
The primary structure of LBD is affected by alternative splicing and RNA editing. In the 
LBD, a part of the upper lobe that forms the dimer interface includes a 38 amino acid long 
segment which as a result of alternative splicing occurs in two alternative forms, the “flip” 
and “flop” splice variants, which differ in 9 to 11 amino acids depending on AMPA receptor 
subunit (Sommer et al., 1990). Flip and flop isoforms exhibit different channel kinetics with 
flip splice variants generally desensitizing four to five times slower than flop variants 
(Mosbacher et al., 1994; Koike et al., 2000). They also show different sensitivities to 
allosteric modulators such as cyclothiazide (Partin et al., 1994; Kessler et al., 2000), 4-[2-
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(phenylsulfonylamino)ethylthio]-2,6-difluoro-phenoxyacetamide (PEPA) (Sekiguchi et al., 
1997; Sekiguchi et al., 1998), zinc (Shen and Yang, 1999), and lithium (aKarkanias and 
Papke, 1999; bKarkanias and Papke, 1999), that fine-tune the kinetics of the receptor channel. 
Moreover, differences in the early trafficking of receptors have been reported with flip and 
flop isoforms. Homomeric GluA1 and GluA4 flop isoforms accumulate in the endoplasmic 
reticulum (ER) possibly through interactions with luminal ER proteins, while flip isoforms 
are efficiently transported to the cell surface (Coleman et al., 2006). The ER retention can be 
rescued with stargazin, a transmembrane AMPA receptor regulatory protein (TARP), or 
through co-expression with flip isoforms (Chen et al., 2000; Coleman et al., 2006).  
 
In addition to the alternative splicing, an amino acid residue at a so-called R/G-site, located 
immediately before the flip/flop region is targeted by RNA editing. The primary RNA 
transcripts of GluA2, GluA3 and GluA4 genes are edited so that the codon AGA, for the 
amino acid arginine (R), is - to varying extent - converted by adenosine deaminase to IGA (I 
standing for inosine which has base-pairing properties of G), encoding the amino acid glycine 
(G) in the translated protein. The resulting editing isoforms (R and G) have different kinetic 
properties. Edited (G) receptors, containing glycine, show quicker resensitization (i.e. 
recovery from desensitization) than the unedited (R) receptors, while the editing has different 
effects on the onset of desensitization rates depending on subunit type (Lomeli et al., 1994; 
Krampfl et al., 2002).  
 
 
 
Figure 4. Schematic representation showing conformational changes in AMPA receptor LBD and TMD 
upon channel activation. The LBD consisting of an upper and lower lobe form a clamshell with a ligand-
binding cleft between the two lobes. The cylinder represents transmembrane segment M3, which move upon 
agonist binding to open the ion channel (inactive in resting state [channel closed], active with ligand bound 
[channel open], desensitized, i.e. inactive with ligand bound [channel closed]). The NTDs and CTDs are omitted 
from the figure for clarity.   
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1.2.1.3 The transmembrane pore-forming region 
The transmembrane domain (TMD) is composed of four membrane-associated segments, 
M1-M4, each composed of largely hydrophobic residues. Three of these (M1, M3, and M4) 
are transmembrane helices, whereas the M2 segment forms a re-entrant pore (P) loop. The 
TMD anchors the receptor to the plasma membrane and forms the ion channel of the receptor 
with a four-fold rotational symmetry (Sobolevsky et al., 2009; Herguedas et al., 2016). In the 
crystal structure, the ion channel is shaped like a pyramid with a cut off top. The broad base 
is facing towards the cytoplasm and the top is extracellular. Agonist binding to the LBD and 
closure of the clamshell leads to movement in three regions linking LBD to TMD, linkers S1-
M1, M3-S2 and S2-M4. This movement pulls apart the M3 helices that line the outer cavity 
of the pore leading to channel opening, i.e. the channel is activated (Sobolevsky et al., 2009).  
 
AMPA receptor channels are permeable to monovalent cations and, in the absence of GluA2 
subunit, to Ca2+. M2 (pore loop) lines the inner cavity of the ion channel pore and determines 
the Ca2+ permeability of the receptor through RNA editing affecting a single residue in the 
so-called Q/R-site in the M2 encoding part of the GluA2 subunit. While the genomic DNA of 
the GluA2 subunit encodes the amino acid glutamine (Q), the majority of GluA2 transcripts 
undergo RNA editing by adenosine deaminase to yield functional GluA2 receptors containing 
an arginine (R), at position 6071. Due to the size and charge of the arginine side chain, the 
receptor channel shows low conductance and permeability to Ca2+ (Sommer et al., 1991; Cha 
et al., 1994; Seeburg et al., 1998; Seeburg and Hartner, 2003 Burnashev et al., 1992; 
Burnashev et al., 1995; Swanson et al., 1997). It has been estimated that the majority (~80%) 
of hippocampal synaptic AMPA receptors are heteromeric GluA2-containing receptors, 
which are calcium-impermeable, while roughly 8% of the total pool of hippocampal AMPA 
receptors are calcium-permeable homomeric GluA1 receptors (Wenthold et al., 1996; Lu et 
al., 2009). 
 
1.2.1.4 The intracellular C-terminal domain 
Compared to the prominent sequence homology amongst the extracellular and 
transmembrane domains of the AMPA receptors, the cytosolic C-terminal tails of different 
AMPA receptor subunits vary in terms of amino acid sequence and length. The AMPA 
receptor CTDs are of two types: short (50 residues) and long (68-80 residues) depending on 
subunit type (Traynelis et al., 2010). GluA1 subunits have a long tail (80-81 residues in 
mammalian species) and GluA3 a short tail. Adding to the diversity of the CTDs is the ability 
of GluA2 and GluA4 to undergo alternative splicing to produce both long- and short-tailed 
isoforms. The majority of GluA2 exists in the short form, while GluA4 is predominantly of 
the long form (Gallo et al., 1992; Köhler et al., 1994). The low degree of sequence homology 
amongst the CTDs of different AMPA receptor subtypes is reflected in differences in post-
translational modifications and protein interactions influencing the intracellular trafficking 
and regulation of the receptor (Figure 5).  
                                                 
1 The amino acid numbering for AMPA receptor subunits, throughout this thesis, is for the total 
protein including the signal peptide (initiating methionine is numbered 1).  
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Importantly, all crystal structures of AMPA receptors have been obtained from deletion 
mutants, which lack the CTD. Thus, there is very little structural information for the CTDs of 
AMPA receptors. Primary sequence analysis algorithms predict that the CTDs of AMPA 
receptors are intrinsically disordered and thus unlikely to adopt a stable fold. Generally, an 
unfolded nature is common for cytosolic CTDs of mammalian membrane proteins and in 
combination with short conserved sequence motifs they are optimal for probing and 
successfully connecting with multiple scaffolding protein partners (Minezaki et al., 2007). 
 
Figure 5. C-terminal AMPA receptor sequences from rat (Gene bank accession number following subunit 
name) showing post-translational modifications (● palmitoylation; ○ ubiquitinylation; + phosphorylation; 
* S-nitrosylation). Numbers to the right indicate the length of the amino acid sequence of the receptor 
(Traynelis et al., 2010 Na et al., 2012; Wagner et al., 2012; Selvakumar et al., 2013). 
 
 
1.2.2 AMPA receptor regulation through C-terminal post-translational modifications 
and protein interactions 
The intracellular C-terminal tails of AMPA receptors contain several sites for reversible post-
translational modifications, such as phosphorylation, ubiquitination, S-palmitoylation and S-
nitrosylation, as well as sites for protein interactions playing critical roles in receptor 
trafficking, localization, and function. In the following chapters, the focus will be on post-
translational modifications of the cytosolic C-terminus of AMPA receptor subunit GluA1 
specifically. Similar post-translational modifications have been described for the other 
subunits, and contribute to their specific functional regulation. 
 
1.2.2.1 Phosphorylation of GluA1 CTD 
Phosphorylation is the addition of a phosphoryl group (PO32-) to threonine, serine and 
tyrosine residues on target proteins. In rare cases histidine, lysine and arginine residues can 
also serve as sites for phosphorylation (Ciesla et al, 2011). The phosphoryl group changes the 
hydrophobicity and electric charge of the protein, as well as the size of its side chain, which 
can result in functional changes due to structural alterations in the protein or due to newly 
gained or lost protein interactions. In glutamate receptors phosphorylation of CTD has been 
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reported to regulate intracellular trafficking and channel properties (Wang et al., 2005; 
Lussier et al., 2015). 
 
In neuronal cultures or slice preparations, the C-terminus of GluA1 is phosphorylated at 
multiple sites by protein kinase C (PKC), cyclic-AMP-dependent protein kinase (PKA) and 
Ca2+/calmodulin dependent protein kinase II (CaMKII) in an activity-dependent manner. 
Phosphorylation of the GluA1 C-tail modulates the gating properties of the receptor channel. 
Phosphorylation at serine residue 849 (S849) by CaMKII increases the single channel 
conductance, whereas phosphorylation of S863 by PKA increases the mean open probability 
of homomeric GluA1 receptors (Roche et al., 1996; Barria et al., 1997; Mammen et al., 1997; 
Derkach et al., 1999). The enhanced conductance of homomeric GluA1 receptors by S849 
phosphorylation can be overhauled by coexpression with the GluA2 subunit (Oh and 
Derkach, 2005). Yet again, the increased effect of S849 phosphorylation can be restored in 
GluA1/GluA2 heteromeric receptors when co-expressed with TARPs (Kristensen et al., 
2011), adding a layer of complexity to the regulation of AMPA receptors through 
phosphorylation. 
 
In addition to the modulatory role on channel properties, phosphorylation of C-terminal 
residues in GluA1 is also regulating the receptor trafficking. Phosphorylation of S863 has 
been shown to drive GluA1 to extrasynaptic sites for subsequent delivery to synapses during 
long-term potentiation (LTP), the long-lasting change on synaptic strength in response to 
synaptic activity, a form of synaptic plasticity essential for learning and memory (Lee et al., 
2003; Oh et al., 2006). For LTP expression, a concomitant phosphorylation of S863, S849 
and S836 is likely needed. Phosphorylation of S849 and S863 lowers the threshold for LTP 
induction (Lee et al., 2003; Lee et al., 2010; Makino 2011), while phosphorylation of S836 
drives the synaptic incorporation of GluA1 and is critical for the LTP expression (Boehm 
2006). 
 
How phosphorylation of GluA1 can influence trafficking and synaptic plasticity is somewhat 
unclear. One plausible explanation is, that phosphorylation can modulate GluA1 protein 
interactions involved in AMPA receptor trafficking. An example of this is the 
phosphorylation of GluA1 CTD residues S834 and S836 by PKC, which enhances the 
interaction between GluA1 and actin-binding protein 4.1N, leading to an increased exocytosis 
of AMPA receptors at extrasynaptic sites and subsequent insertion in synapses at LTP 
induction (Lin et al., 2009). 
 
Long-term depression (LTD), the activity-dependent removal of AMPA receptors from 
synaptic sites, on the other hand, depends solely on dephosphorylation of S863, but not of 
S849 (Lee et al, 1998; Kameyama et al, 1998; Lee et al., 2003; Lee et al., 2010). Moreover, a 
decrease in the GluA1 phosphorylation on threonine 858 (T858), after NMDA receptor 
induced activity, has been implicated in LTD as well (Lee et al., 2007; Delgado et al., 2007). 
 
  
18 
 
1.2.2.2 Ubiquitination of GluA1 CTD 
Many cellular processes such as protein turnover, apoptosis, cell-cycle progression, 
transcriptional regulation, trafficking and receptor down-regulation by endocytosis are 
regulated by a small 76 amino acids long ubiquitously expressed protein, ubiquitin. 
Ubiquitination (also known as ubiquitylation) is a reversible post-translational modification 
where ubiquitin is covalently linked to lysine, cysteine, threonine or serine residues or to the 
N-terminal amino group of target proteins catalyzed by ubiquitin ligases and reverted by 
deubiquitinating proteases (deubiquitinases). Ubiquitination generally steers proteins to 
degradation by proteasomes (Breitschopf et al., 1998; Hershko and Ciehanover, 1998; 
Cadwell and Coscoy, 2005; Wang et al., 2007). 
 
Ubiquitination is also an important molecular mechanism regulating the synaptic function. 
All mammalian AMPA receptors are subject to ubiquitination on specific C-terminal lysine 
residues in an activity- and Ca2+-dependent manner. The process requires the activity of L-
type voltage gated Ca2+ channels and CaMKII. Receptor activation leads to endocytosis and 
subsequent lysosomal accumulation and degradation of ubiquitinated AMPA receptors. It 
seems however, that AMPA receptor activity-induced receptor endocytosis is not due to 
ubiquitination per see, as ubiquitination of the receptor only occurs after internalization. 
Analysis of C-terminal lysine mutants pinpoints one ubiquitination site in GluA1, the lysine 
886 (K886) (Widagdo et al., 2015).  
 
1.2.2.3 GluA1 palmitoylation  
Glutamate receptors, as well as several other proteins in glutamatergic synapses are regulated 
through S-palmitoylation, the reversible and covalent addition of palmitic acid (palmitate), a 
16-carbon saturated fatty acid, to cysteine residues of target proteins. The cysteines sensitive 
for palmitoylation, by palmitoyl acyl transferases, are surrounded by basic and hydrophobic 
residues and located in close vicinity of the cytosolic inner face of the hydrophobic cell 
membrane. Palmitoylation increases the hydrophobicity of proteins thus generally facilitating 
membrane insertion. In addition to stabilizing proteins at the plasma membrane, 
palmitoylation regulates the intracellular trafficking of proteins. AMPA receptor subunits are 
palmitoylated at two conserved cysteine residues located in close vicinity of the cytosolic 
face of the membrane, one located on the C-terminal tail and the other on the intracellular 
loop between M2 and M3. It has been reported that the cyclic action of palmitoylation and 
depalmitoylation (by palmitoyl thioesterases) of AMPA receptors, or their interacting 
proteins, facilitates dynamic control of receptor trafficking. Palmitoylation on the 
intracellular loop between M2 and M3, close to the channel pore, of GluA1 and GluA2 leads 
to an accumulation of the receptor in the Golgi and a reduction of receptor surface expression 
(Hayashi et al., 2005; Yang et al., 2009; Han et al., 2015). Palmitoylation of the membrane 
proximate cysteine in the GluA1 C-terminal tail also decreases the cell surface trafficking of 
the receptor by destroying the interaction to protein 4.1N having a pivotal role in stabilizing 
the receptors at the cell surface (Shen et al., 2000; Coleman et al., 2003; Hayashi et al., 2005). 
Of note, AMPA- (and NMDA-) receptor activity induced by glutamate rapidly 
depalmitoylates the AMPA receptors promoting surface trafficking (Hayashi et al., 2005).  
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1.2.2.4 S-nitrosylation at glutamatergic synapses 
Nitric oxide (NO) is an unstable and reactive gaseous signaling molecule with important roles 
in immune defense, regulation of vascular function and neuronal plasticity. NO exerts its 
biological effects through at least two distinct molecular mechanisms. Firstly, NO binding 
activates soluble guanylyl cyclase (sGC) leading to the formation of a second messenger, 
cyclic guanosine monophosphate (cGMP), involved in downstream signaling cascades. 
Secondly, through a covalent reversible and non-enzymatic post-translational modification, 
called S-nitrosylation, NO is attached to thiol (-SH) moieties of cysteine residues generating 
S-nitrosylated proteins (S-nitrosoproteins [-SNO]) with modified functions (Broillet, 1999). 
The term S-nitrosylation was coined in 1992 (Stamler et al., 1992; Nakamura and Lipton, 
2011) to this process involving NO, in analogy with phosphorylation and the phosphoryl 
group PO32-. NO is produced from arginine and molecular oxygen by the enzyme nitric oxide 
synthase (NOS) through a two-step reaction (Figure 6). There are three mammalian isoforms 
of NOS, the neuronal nitric oxide synthase (nNOS; NOS1), the inducible nitric oxide 
synthase (iNOS; NOS2) and the endothelial nitric oxide synthase (eNOS; NOS3). The nNOS 
and eNOS are constitutively expressed in cells and their activity is regulated by Ca2+ via 
Ca2+-binding protein calmodulin (CaM). At basal concentrations, nNOS and eNOS are 
inactive, but in response to an elevated intracellular Ca2+ concentration Ca2+/CaM bind to 
nNOS and eNOS activating the enzyme resulting in NO synthesis. iNOS binds CaM 
permanently at physiological Ca2+ concentrations and is typically induced during 
inflammation to produce NO as an immune defense mechanism. As a free radical with an 
unpaired electron, NO can easily be converted to harmful nitrites and nitrates when 
synthesized in excess (Knowles and Moncada, 1994; Stuehr, 1999; Bradley and Steinert, 
2016). 
 
Figure 6. Reaction step for NO production. NOS catalyzes the production of NO and L-citrulline from L-
arginine and oxygen with electrons donated from NADPH. As a by-product two molecules of water are formed. 
Chemical structures were obtained from the ChemSpider database (www.chemspider.com), with oxygen and 
hydroxyl groups in red and amine groups in blue.  
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S-nitrosylation of protein thiols was demonstrated for the first time in the early nineties 
(Stamler et al., 1992) and in 2001, Jaffrey and co-workers introduced a method, the so-called 
biotin-switch assay, to selectively biotinylate nitrosylation sites in proteins. By swopping the 
labile NO to a stable biotin molecule, they were able to detect several proteins endogenously 
S-nitrosylated by nNOS in brain tissue by a simple affinity precipitation utilizing 
streptavidin-sepharose. Since then an ever-growing number of proteins have been shown to 
be subject to S-nitrosylation. 
 
In the brain, NO signaling has been reported to regulate several important molecules in 
glutamatergic synapses through reversible cysteine S-nitrosylation, such as NMDA receptors 
(Choi et al., 2000; Choi and Lipton, 2000), kainate receptors (Zhang et al., 2012) and 
stargazing (Selvakumar et al., 2009). The effects of NO on glutamate receptors can be 
mediated indirectly via S-nitrosylation of interacting proteins or directly through S-
nitrosylation of receptors themselves, influencing their trafficking, signaling, localization and 
function and by doing so, modulating normal physiological processes such as neuronal 
survival and synaptic plasticity. 
 
NO signaling regulates also AMPA receptors, both via cGMP-pathway and S-nitrosylation 
(Serulle et al., 2007; Vielma et al., 2014; Selvakumar et al., 2009; Selvakumar et al., 2013; 
Selvakumar et al., 2014). Recently, it was reported that C-terminal cysteines in GluA1 are 
nitrosylation targets regulating receptor conductance and endocytosis. S-nitrosylation of 
GluA1 CTD residue C893 was reported to augment S849 phosphorylation and facilitate an 
increase in the conductance of AMPA receptors, and to promote endocytosis by increasing 
the interaction between GluA1 and AP2 (Selvakumar et al., 2013), a protein participating in 
clathrin-mediated endocytosis (Pearse et al., 2000).  
 
1.2.2.5 GluA1 C-terminal protein interactions 
In addition to several post-translational modification sites, the C-terminus of GluA1 contains 
binding sites for interacting proteins regulating cellular trafficking and/or surface expression 
of GluA1 containing receptors with minor differences in their spatio-temporal association to 
GluA1 (Figure 7).  
 
 
Figure 7. C-terminal sequence of GluA1. Post-translational modifications (● palmitoylation; ○ 
ubiquitinylation; + phosphorylation; * S-nitrosylation) and protein interactions indicated.  
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1.2.2.5.1 PDZ domain mediated GluA1 C-terminal interactions 
The C-terminus of GluA1 harbors a C-terminal class I PDZ binding motif (see chapter 
1.3.2.2) that has been reported to bind to PDZ domain containing proteins SAP97 (Leonard et 
al., 1998), mLin-10 (Stricker and Huganir, 2003), Shank (Uchino et al., 2006) and sorting 
nexin 27 (Hussain et al., 2014; Loo et al., 2014). The interaction between SAP97 and GluA1, 
as well as its role in neuronal function will be discussed in detail in chapter 1.3. Shank3 is a 
PDZ domain containing scaffolding protein expressed in the spines of developing neurons 
where it was reported to associate with the surface expressed pool of GluA1 receptors. In 
addition to Shank3, two other members of the Shank family (Shank1 and Shank2) were 
reported to bind GluA1 CTD (Uchino et al., 2006). Sorting nexin 27 has been reported to 
bind, via its PDZ domain to GluA1 and promote receptor re-cycling to the cell surface 
(Hussain et al., 2014; Loo et al., 2014). Unlike Shank3 and sorting nexin 27, mLin-10 
associates not only with GluA1, but also with GluA2 that lacks a class I PDZ binding motif 
(but has a class II motif instead). Consistent with an unconventional nature of this PDZ 
interaction, a deletion of the 15 last C-terminal residues in GluA1 only reduces but does not 
completely abolish the interaction. The interaction with mLin-10 is suggested to regulate 
GluA1 trafficking as a PDZ point mutation enhances the surface expression of AMPA 
receptors (Stricker and Huganir, 2003).  
 
1.2.2.5.2 Non-PDZ domain mediated GluA1 C-terminal interactions 
In addition to the GluA1 interacting protein 4.1., discussed earlier in the context of C-
terminal post-translational modifications, other non-PDZ domain mediated C-terminal GluA1 
interacting proteins include the reversion-induced LIM protein (RIL) (Schulz et al., 2004), 
the cGMP-dependent protein kinase II (cGKII) (Serulle et al., 2007) and the α/β-Hydrolase 
domain-containing 6 (ABHD6) (Wei et al., 2016). RIL is enriched at excitatory synapses 
where it plays a role in the endosomal re-cycling. Through its LIM domain RIL binds to 
GluA1 and via its PDZ domain it binds to actin and is able to promote surface expression of 
internalized GluA1 receptors (Schultz et al., 2004). cGKII, is another protein that has been 
reported to promote surface expression of GluA1 receptors. GluA1 binds to cGKII in vicinity 
of the catalytic site of the kinase and the binding increases when cGKII is activated by 
cGMP. When activated, cGKII phosphorylates GluA1 at site S863 thus enhancing surface 
expression of GluA1 (Serulle et al., 2007). The binding of GluA1 to ABHD6 on the other 
hand reduces the surface expression of receptors and excitatory postsynaptic responses (Wei 
et al., 2016). 
 
1.3 SAP97 
 
1.3.1 SAP97 - PDZ binding partner of GluA1 and a member of the MAGUK disks large 
(DLG) subfamily 
SAP97, also known as Disks large homolog 1 (DLG1), is a cytosolic protein with a 
calculated molecular mass of 97 kDa which is ubiquitously expressed not only in brain, but 
also throughout the body, often at sites for cell-to-cell contact (Müller et al., 1995). SAP97 
belongs to the MAGUK family of scaffolding proteins that facilitate efficient cell-to-cell 
communication by clustering cytoskeletal proteins, receptors, signaling molecules, and 
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adhesion molecules at specific locations in the cell. The MAGUKs are divided into 10 
subfamilies according to sequence comparisons. These subfamilies are: discs large (DLG), 
DLG5, zona occludens (ZO), calcium/calmodulin-dependent protein kinase (CASK), 
membrane protein palmitoylated 1 (MPP1), MPP2-7, MPP5, caspase recruitment domain 
containing MAGUK protein (CARMA), calcium channel β subunit (CACNB), and MAGUK 
with an inverted repeat (MAGI) (de Mendoza et al., 2010; Zheng et al., 2011; Oliva et al., 
2012). SAP97 (Lue et al., 1994; Müller et al., 1995) belongs to the DLG subfamily of 
MAGUKs together with three other members, the postsynaptic density protein 93 (PSD-93; 
DLG2) (Kim et al., 1996), synapse-associated protein 102 (SAP102; DLG3) (Müller et al., 
1996) and postsynaptic density protein 95 (PSD-95; DLG4) (Cho et al., 1992; Kistner et al., 
1993).  
 
The physiological importance of SAP97 is demonstrated by the phenotype of null mutant 
mice for the Dlg1 gene. Mice devoid of SAP97 express defects in several organs and die 
shortly after birth due to severe developmental abnormalities in the cardiovascular system 
obstructing normal respiration (Iizuka-Kogo et al., 2015). Moreover, the loss of DLG, the 
sole DLG MAGUK member in Drosophila results in an uncontrolled cell proliferation and 
lethality in Drosophila larvae (Woods and Bryant, 1989; Woods and Bryant, 1991). A 
conditional knock-out of SAP97 in motor neurons leads to a reduction in the dendritic 
branching and overall dendritic tree size as well as reduced dendrite length (Zhou et al., 
2008). While SAP97 is omnipresent, being expressed in the brain and in most other organs 
and tissues, the other members of the DLG subfamily of MAGUKs localize predominantly to 
the CNS (Cho et al., 1992; Kistner et al., 1993; Müller et al., 1995; Müller et al., 1996; Kim 
et al., 1996; Aoki et al., 2001). The spatio-temporal expression pattern of SAP97 and the 
other DLGs in the brain are partly overlapping. DLG MAGUK immunoreactivity can be 
found in a variety of brain regions such as the cerebellum, hippocampus and cerebral cortex 
(Cho et al., 1992; Müller et al., 1995; Kim et al., 1996; Müller et al., 1996; Sans et al., 2000). 
PSD-95 and PSD-93 expression is low in embryonic and early postnatal rat brain tissue and 
increases in juvenile (from postnatal day 15 onwards) and adult tissue (Cho et al., 1992; 
Kistner et al., 1993; Hsueh and Sheng, 1999; Sans et al., 2000), while SAP97 expression is at 
its highest in juvenile rat brain tissue with slowly decreasing expression in adult tissue 
(Müller et al., 1995). The temporal expression of SAP102 differs from the other members of 
the DLG subfamily, with an earlier onset of expression and a rapid decline before adulthood. 
High levels of SAP102 can be detected in rat cerebral cortex and hippocampus already at 
postnatal days 1 and 2, with a clearly detectable decline in expression after postnatal day 30 
(Müller et al., 1996; Sans et al., 2000).  
 
1.3.2 Modular structure of SAP97 and other DLG MAGUKs  
The DLGs contain several protein interaction domains: three PDZ domains, owing their name 
to three proteins in where the domain was originally discovered (the postsynaptic density 
protein PSD-95, the tumor suppressor protein disks large 1 of Drosophila [Dlg] and the tight 
junction protein Zona Occludens-1 [ZO-1]), one Src Homology 3 domain (SH3 domain) and 
one catalytically inactive guanylate kinase-like domain (GUK domain) (Mayer et al., 1988; 
Berger et al., 1989; Woods and Bryant, 1989; Woods and Bryant, 1991; Cho et al., 1992; 
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Gaidarov et al., 1993; Willott et al.,1993; Zschocke et al., 1993; Kistner et al., 1995; Stahl et 
al., 1988). 
 
1.3.2.1 Alternative splicing of DLGs 
All members of the DLG subfamily of MAGUKs are subject to alternative splicing producing 
several structural variants (Figure 8). The N-terminus of SAP97, PSD-93 and PSD-95 is 
composed either of an approximately 50-60 amino acids long L27 heterodimerization domain 
(“β-isoform”), a protein interaction domain initially found in Caenorhabditis elegans proteins 
Lin-2 and Lin-7, or a 10 residues long sequence containing two palmitoylated cysteines (“α-
isoform”) (Doerks et al., 2000; aChetkovich et al., 2002; Schlüter et al., 2006). The majority 
of SAP97 in the CNS is of the β-isoform while PSD-95 in the brain is predominantly of the 
palmitoylated α-isoform, as only ~ 10% of PSD-95 exists in the β-isoform (aChetkovich et al, 
2002; Schlüter et al., 2006). The α- and β-isoforms bestow proteins with distinct 
characteristics. The L27 domain containing β-isoforms are able to form homo- and 
heteromers with other L27 domain containing proteins and thus increase their capacity of 
clustering membrane channels (and other proteins bound to the DLGs) at specific locations in 
the cell and forming multiprotein complexes to facilitate efficient signaling (Marfatia et al., 
2000; Lee et al., 2002; Nakagawa et al., 2004). Although all DLGs can be found both 
presynaptically and postsynaptically, along the plasma membrane or within the cytoplasm, 
PSD-95 is most typically found postsynaptically, where roughly half of the protein is 
anchored firmly in the PSD through the two palmitoylated N-terminal cysteines while the 
other half is non-synaptic (Al-Hallaq et al., 2001; Aoki et al., 2001). SAP97 localizes both to 
presynaptic and to postsynaptic sites. On the postsynaptic neuron, SAP97 is present in the 
PSD but mostly found at perisynaptic sites surrounding the PSD (Müller et al., 1995; 
DeGiorgis et al., 2006; Waites et al., 2009). PSD-93 and SAP102 are also typically localized 
to the post-synaptic site, where PSD-93 shows a cellular distribution similar to PSD-95 in the 
PSD (likely due to the two palmitoylated N-terminal cysteines present in PSD-93 but lacking 
in SAP102), while SAP102 shows a broader distribution within the spine (Al-Hallaq et al., 
2001; DeGiorgis et al., 2006; Zheng et al., 2010). The subcellular localization within the 
postsynaptic cell, into synaptic and non-synaptic compartments, suggests dual roles for the 
DLGs in the synapses: in the PSD, the DLGs maintain receptors at the synapse, while the 
non-synaptic DLGs may bind a reserve pool of receptors that are transported to the plasma 
membrane by the DLGs when needed. 
 
Beside the far N-terminal splicing producing the α- and β-isoforms, the SAP97 polypeptide 
has internal regions affected by alternative splicing. Between the N-terminus and the first 
PDZ domain, two different short insertions may be added after residue 161 to produce I1A 
and I1B isoforms. The N-terminal segment preceding the first PDZ domain is involved in 
intra- and intermolecular association with SH3 domains (Lue et al., 1994; Wu et al., 2000; 
McLaughlin et al., 2002; Cai et al., 2006). A similar alternatively spliced N-terminal region 
has been reported for SAP102 (Müller et al., 1996). The third alternatively spliced region in 
SAP97, situated between the SH3 and GUK domains, called the Hook region, contains four 
alternatively spliced insertions named I2, I3, I4 and I5 (Lue et al., 1994; Mori et al, 1998; 
McLaughlin et al., 2002). Alternative splicing of the Hook region is documented for PSD-93 
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and SAP102 as well (Kim et al., 1996; Müller et al., 1996). The I3 insertion is unique to 
SAP97. SAP97 containing the insertion I3 localizes to the plasma membrane and sites of cell-
to-cell contact. The I3 insertion is involved in binding to 4.1N protein, an interaction critical 
for cell surface and synaptic targeting of SAP97 and its associated AMPA receptors (Lue et 
al., 1994; McLaughlin et al., 2002; Rumbaugh et al, 2003). The I2 insertion on the other 
hand, gives SAP97 a more diffuse expression pattern in the soma and in the dendrites, and a 
proposed nuclear-targeted expression (McLaughlin et al., 2002; Rumbaugh et al, 2003; 
Roberts et al., 2007). Functional effects of I4 and I5 insertions are less well characterized. 
 
Figure 8. Modular structure of DLGs. Illustration of the domain organization and splice variants of SAP97. 
All DLG MAGUKs share the same overall architecture as they consist of three PDZ domains, an SH3 domain 
and a GUK domain. In addition SAP97, PSD-95 and PSD-93 contain either an N-terminal L27 domain or two 
cysteines that can be post-translationally modified. The alternative splice forms I1a/I1b and I3 are unique for 
SAP97 (Adapted from Fourie et al., 2014). 
 
 
1.3.2.2 The PDZ domains 
The PDZ domains are ~90 amino acids long globular protein interaction domains often 
coexisting with other modular protein interaction domains within the same protein (Cho et 
al., 1992; Willott et al., 1993; Woods and Bryant, 1993). Each protein interaction domain in 
the scaffold protein have their own interacting partners, and in this way PDZ containing 
scaffold proteins can cluster large multiprotein complexes at defined compartments in the 
cell, thus facilitating efficient signal transduction (Sheng & Sala, 2001; Nourry et al., 2003; 
Kim and Sheng, 2004). The PDZ domain is one of the most abundant protein interaction 
domain and over 260 non-redundant PDZ domains have been reported to be encoded by the 
human proteome (Luck et al., 2012). It can be found in a variety of species ranging from 
bacteria and yeast to mammalian species (Ponting, 1997). 
 
Typically, PDZ domains bind to a short C-terminal binding motif on their target proteins and 
can be classified into three major types based on the consensus sequence of the last four C-
terminal amino acids of their ligands. PDZ domains of SAP97 and the other members of the 
DLG subfamily recognize class I PDZ binding motifs: -S/T-X-Ф (S/T standing for a serine or 
threonine, X standing for any amino acid, and Ф standing for a hydrophobic C-terminal 
amino acid). Based on structural studies, the canonical PDZ domain contains five to six β-
strands (βA-βF) and two α-helices (αA and αB). The C-terminal peptide ligands bind to a 
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groove between the βB strand and the αB helix. The ligand peptide assumes an extended 
form antiparallel to the βB strand with main chain contacts with the βB strand. A loop, the so-
called carboxylate binding loop, between βA and βB strands containing a conserved repeat of 
amino acids, -G-L-G-F-, docks the carboxylate group of the ultimate C-terminal amino acid 
(at position P0) of the ligand via hydrogen bonds to main chain amides and forms a 
hydrophobic pocket accommodating the aliphatic side chain of the C-terminal residue. In 
addition, an arginine (or lysine) residue in the carboxylate binding loop, preceding the –G-L-
G-F- repeat interacts with the carboxylate via a water molecule. The requirement for a S/T 
residue at the third to last position P-2 of the PDZ ligand is explained by a hydrogen bond 
which forms between the hydroxyl oxygen of S/T residues and a conserved histidine residue 
at the N-terminal end of the αB helix (the αB1 position) in class I PDZ domains (Doyle et al., 
1996) (Figure 9). In addition to class I PDZ binding motifs and domains, there are class II 
and class III PDZ domains which contain different amino acids at position αB1 than histidine 
with preferences for ligands with hydrophobic amino acids (class II PDZ binding motif; -X-
Ф-X-Ф) or negatively charged amino acids (class III PDZ binding motif; -X-D/E-X-V) at the 
antepenultimate P-2 position (Sheng and Sala, 2001). 
 
 
 
 
Figure 9. Canonical class I PDZ interaction (PSD-95PDZ3 and CRIPT peptide). (A) The PDZ3 structure of 
PSD-95 in complex with a CRIPT peptide showing a typical PDZ fold comprising two α-helices (αA, αB) and 
six β-strands (βA-βF). The peptide (green) is situated in a groove between the βB strand and the αB helix. (B) 
Canonical class I PDZ interaction in the peptide binding groove through contacts made by the ultimate and 
penanteultimate residue of the peptide (the last four amino acid residues of the peptide [green stick] is shown in 
the peptide binding groove) to the carboxylate binding loop (-G-L-G-F-) and the αB helix. For clarity only 
hydrogen bonds between the ultimate C-terminal amino acid valine at position P0  and main chain amides of 
conserved residues in the carboxylate binding loop and the hydrogen bond between threonine in position P-2 and 
the conserved histidine at the N-terminal end of the αB helix are shown.  
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In addition to short C-terminal peptide ligands, PDZ domains have been shown to interact 
with internal peptides, β-hairpin structures and phospholipids (Figure 10) (Sheng and Sala, 
2001; Nourry et al., 2003). To accommodate internal peptide ligands in the peptide binding 
groove, with amino acids extending beyond the position P0, the PDZ domain has to undergo 
structural changes. The three-dimensional structure of Par-6 PDZ domain in complex with 
the internal Pals1 peptide ligand shows that peptide binding induces a conformational change 
in the carboxylate binding loop, likely due to a salt bridge between an aspartic acid at 
position P+1 of the ligand and a conserved lysine residue in the carboxylate binding loop 
(Penkert et al., 2004). Internal peptides can also fold into a β-hairpin to overcome the steric 
hindrance presented by the carboxylate binding loop. PDZ binding to a hairpin structure is 
exemplified by the nNOS-PSD-95 -complex, which is a PDZ-PDZ complex. The PDZ 
domain of nNOS contains a C-terminal extension that folds back to adopt a β-strand structure 
that fits in the carboxylate binding groove of PSD-95 PDZ (Hillier et al., 1999; aTochio et al., 
2000; bTochio et al., 2000). It has been estimated that up to 40% of PDZ domains interact 
with plasma membrane phospholipids (Chen et al., 2012). Phospholipid binding to PDZ 
domain is, however, not restricted to the peptide binding groove, but instead phospholipids 
can bind to structurally distinct regions on the PDZ domain. By separating the lipid binding 
site to regions close or distal from the peptide binding site the phospholipid binding can 
either compete with peptide binding or work in synergy and thus participate in the regulation 
of PDZ function (Chen et al., 2012; Ivarsson, 2012).  
 
Figure 10. PDZ binding through: C-terminal peptide, β-hairpin, deformed carboxylate-binding loop 
(Adapted from Penkert et al., 2004). 
 
 
1.3.2.3 The SH3 and GUK domains 
The SH3 and GUK domains, like the PDZ domains, are mediating purely protein-protein 
interactions. Typically the SH3 domains bind ligands with a proline-rich conserved binding 
motif, -P-X-X-P- (P standing for proline and X standing for any amino acid), with modest 
affinity and selectivity. However, the SH3 domain of DLG MAGUKs differ from the typical 
SH3 domains as they contain a hinge (Hook) insert that replaces a short helix containing a 
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conserved tyrosine crucial for canonical peptide binding, which is present in other SH3 
domains. In addition, the SH3 domain of DLG MAGUKs is structurally discontinuous as the 
most C-terminal β-strand (βF) in DLG MAGUK SH3 domains is situated only after the GUK 
domain (McGee et al., 2001). With the exception of PSD-95 SH3 domain reported to bind to 
GluK5 kainate receptor CTD (Garcia et al., 1998), no specific binding partners have been 
identified for the SH3 domains of SAP97 and the other DLG MAGUKs. Instead, the SH3 
domains of DLGs participate in intra- and intermolecular homo- and heterotypic interactions 
with the GUK domain and with proline-rich N-terminal sequences in DLGs. These SH3 
domain interactions are atypical, as no proline-rich binding motifs are present in the GUK or 
NTD regions (McGee and Bredt, 1999; McLaughlin et al., 2002). Although named guanylate 
kinase homology domain, the GUK domain is catalytically inactive due to lack of critical 
amino acid residues needed for guanylate kinase catalyzed ATP-dependent phosphorylation 
of GMP to GDP (Lue et al., 1994; Kistner et al., 1995), and is believed to mediate specific 
protein interactions instead. The intramolecular interactions between SH3 and GUK domains 
or SH3 and N-terminal sequences can regulate the binding between GUK and other proteins. 
In SAP97, the intramolecular interaction between SH3 Hook region and GUK hinders the 
interaction between GUK and the GUK associated protein (GKAP). However, an 
intramolecular interaction between an N-terminal sequence (situated between the L27 and 
PDZ1 domains) and SH3 in SAP97 alters the SAP97 conformation facilitating GKAP 
binding (Wu et al., 2000). The crystal structure of SH3-GUK of SAP97 in complex with a 
mitotic spindle regulatory protein LGN peptide showed that the GUK domain mediated 
binding to target proteins involves recognition of a phosphorylated serine/threonine residue. 
Within all members of the DLG MAGUKs the residues forming the phospho-serine/threonine 
binding pocket are absolutely conserved, and therefore, the GMP-binding site of GUK 
domains have likely evolved to bind phosphorylated ligands (Zhu et al, 2011). 
 
1.3.2.4 Supramodules 
Although the binding specificity of PDZ domains is often determined by recognition of only 
a few residues at the C-terminus of their target proteins by the ligand-binding groove of the 
PDZ domain, for some PDZ domains structures and sequences beyond their canonical PDZ 
fold contribute to specificity, affinity and regulation of the interaction with their targets. 
These so-called extended PDZ domains include individual PDZ domains with short 
extensions in their N- or C-terminus, multiple PDZs in tandem arrays (homotypic 
supramodules) or PDZ domains acting in concert with other protein interaction domains such 
as SH3 or/and GUK (heterotypic supramodules) (Feng and Zhang, 2009; Ye and Zhang, 
2013).  
 
PSD-95, the prototypical member of DLG subfamily of MAGUKs, can form extended PDZ 
domains through a C-terminal extension (PDZ3- helix αC) as well as homotypic (PDZ1-
PDZ2) and heterotypic supramodules (PDZ3-SH3-GUK). The first canonical PDZ interaction 
resolved by X-ray crystallography was the PSD-95 PDZ3 in complex with a C-terminal 
peptide from cysteine-rich interactor of PDZ3 (CRIPT) (Doyle et al., 1996). PSD-95 PDZ3 
contains a C-terminal extension folding to an α-helix bending towards the peptide binding 
groove (Figure 11). This additional element, the so-called helix αC (or helix α3), was not 
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discussed in the original paper by Doyle and co-workers, but subsequent work has shown that 
the αC helix participates in the ligand-PDZ interaction by making contact up to the eight 
residue on the ligand extending from the canonical peptide binding groove. A deletion of the 
αC helix does not change the overall structure of PSD-95 PDZ3, but the affinity towards C-
terminal peptides is substantially reduced (Petit et al., 2009; Chi et al, 2012).  
 
Figure 11. Extended PDZ domain. PSD-95PDZ3 with a C-terminal extension. The figure is drawn with PyMol 
(pdb coordinates 1IE9). 
 
 
All DLG MAGUKs have been reported to partition into homotypic PDZ1-PDZ2 
supramodules and heterotypic PDZ3-SH3-GUK supramodules in solution (Figure 12) 
(McCann et al., 2012; Zhang et al., 2013). Studies on the PSD-95 PDZ1-PDZ2 tandem, 
connected by a short eight residues long conserved linker, have demonstrated that peptide 
binding has a strong effect on domain orientation (Wang et al., 2009) and that the tandem is 
capable of both antiparallel and parallel alignment of the individual binding pockets (Figure 
13) (Long et al., 2003; Sainlos et al., 2011; McCann et al., 2011). The orientations of the 
ligand binding sites have implications for the PSD-95 ligand selection. PSD-95 binds 
multiple ligands, such as the short C-terminal tails of several membrane proteins as well as 
sizable cytosolic proteins such as nNOS. Short C-terminal peptide sequences by membrane 
proteins are able to co-occupy parallel binding pockets in the PSD-95, which is how PSD-95 
is suggested to cluster membrane channels and receptors (Long et al., 2003). Co-occupancy 
of PDZ1-PDZ2 by a C-terminal tail of a membrane protein and nNOS is most likely through 
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antiparallel binding pockets, since the size of nNOS could present steric hindrance on co-
occupancy if the binding sites were aligned.  
 
 
 
Figure 12. Extended PDZ domain. Cartoon model for the supertertiary conformation of PSD-95 showing 
partitioning into two independent supramodules: the PDZ1-PDZ2 tandem and the PDZ3-SH3-GUK 
supramodule (Adapted from McCann et al., 2012). 
 
 
 
The structures of SH3-GUK (McGee et al, 2001; Tavares et al., 2001; Zhu et al., 2011) and 
PDZ3-SH3-GUK (Pan et al., 2011; Nomme et al., 2011; Zhang et al., 2013) segments of 
PSD-95, SAP97 and ZO-1 show that the individual domains are packed tightly as 
supramodules and able to influence each other’s binding properties. In the PSD-95 SH3-GUK 
supramodule (McGee et al., 2001; Tavares et al., 2001) the two last C-terminal β-strands (βE 
and βF) of SH3, separated by the GUK domain, form an antiparallel β-sheet clasping the 
domains close together to form a structurally integrated unit. In addition, the ZO-1 PDZ3-
SH3-GUK supramodule shows that the PDZ3 domain makes direct contact with the SH3-
GUK domain (Pan et al., 2011). Albeit similar, the ZO-1 and PSD-95 PDZ3-SH3-GUK 
supramodule structures differ slightly. The first difference is in the peptide binding. In ZO-1, 
the peptide makes contacts to both PDZ3 and SH3 domains likely stabilizing the 
intramolecular interaction, whereas in PSD-95, the association between PDZ3 and SH3 is 
disrupted upon ligand binding. A second difference is that the PDZ3 domains of ZO-1 and 
PSD-95 occupy different locations in the domain complex, possibly due to differences in the 
length of linker between PDZ3 and SH3. Furthermore, the peptide binding groove of PDZ3 in 
ZO-1 points towards the solution, away from the SH3 domain, while the peptide binding 
groove of PDZ3 in PSD-95 is situated between the PDZ3 and SH3 domains (Zhang et al., 
2013).  
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Figure 13. Possible orientations of PDZ1-PDZ2 tandem influencing their function. A parallel arrangement 
of the peptide binding grooves enables the MAGUK proteins to cluster receptors by binding to their short C-
terminal tails at the cell membrane and enhances their affinity to receptors through multivalency. Through 
antiparallel arrangement on the other hand, the MAGUK molecule is able to interact simultaneously with C-
terminal tails of membrane bound proteins and sizable cytosolic proteins in a rather limited space offered in the 
PSD of a synapse (Modified from Long et al., 2003; McCann et al., 2011). 
 
 
1.3.3 SAP97 – GluA1 interaction 
SAP97 is the only member of the DLG subfamily of MAGUKs capable of binding the 
AMPA-type glutamate receptor GluA1 through a direct interaction. In principle, the 
interaction is a canonical class I PDZ interaction between the second PDZ domain of SAP97 
and the short PDZ binding motif (-A-T-G-L) residing in the ultimate C-terminus of GluA1 
(Leonard et al., 1998). The threonine at position P-2 and leucine at position P0 of GluA1 are 
important for the interaction, as mutations to alanine in these residues abolish the interaction 
between GluA1 and SAP97 (Cai et al., 2002). In addition to the short PDZ binding motif, a 
tripeptide sequence (-S-S-G-) located 9-11 residues upstream from the C-terminus of GluA1 
has been found to contribute to the interaction (Cai et al., 2002).  
 
1.3.4 SAP97 and GluA1 –role in neuronal development and synaptic function 
In the brain, SAP97 has several roles in the development of glutamatergic synapses. 
Although SAP97 is not believed to participate in the initial steps of synaptogenesis its 
expression in brain, and that of the other members of the DLG subfamily, quickly picks up 
and peaks at around postnatal day 15 in rats (Cho et al., 1992; Kistner et al., 1993; Müller et 
al., 1995; Müller et al., 1996; Hsueh and Sheng, 1999; Sans et al., 2000). This time coincides 
with the period when developing pups begin to hear and open their eyes for the first time and 
when the newly established synapses are molded. A number of studies indicate that SAP97 
together with PSD-95 and PSD-93 play an important role in the trafficking of glutamate 
receptors and signaling molecules to these newly formed synapses (Chen et al., 2000; El-
Husseini et al., 2000; Sans et al., 2001; Rumbaugh et al., 2003; Ehrlich and Malinow, 2004; 
Elias et al., 2006; Howard et al., 2010; Zheng and Keifer, 2014). Overexpression of SAP97, 
the only member of the DLG family capable of direct interaction with both AMPA and 
NMDA receptors (Leonard et al., 1998; Bassand et al., 1999; Cai et al., 2002), increases the 
amount of synaptic GluA1 and the frequency of miniature excitatory postsynaptic currents 
(Rumbaugh et al., 2003; Nakagawa et al., 2004). 
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1.3.4.1 SAP97 and GluA1 in synaptic plasticity  
The synaptic connections are continuously remodeled, strengthened or rendered weaker, in 
response to neuronal activity in a process called synaptic plasticity. Repetitive synaptic 
activity triggers NMDA receptor activation and a subsequent rise in the intracellular Ca2+-
level, critical for the induction of long-term potentiation (LTP) or long-term depression 
(LTD), long lasting changes in the synaptic efficacy due to insertion or removal of AMPA 
receptors, respectively, at synaptic sites (Lüscher and Malenka, 2012; Herring and Nicoll, 
2016). The insertion of calcium-permeable GluA1 containing AMPA receptors to the synapse 
is essential for LTP expression and implicated in learning and memory formation (Shi et al., 
1999; Hayashi et al., 2000; Shi et al., 2001; Lee et al., 2003; Lynch, 2004; Plant et al., 2006).  
 
As discussed in chapter 1.3.2.1, SAP97 and PSD-95 exists as two alternatively spliced 
isoforms containing either a shorter palmitoylated N-terminus (α-isoform) or an N-terminal 
L27 domain (β-isoform). The unique N-terminal sequences confer the isoforms with different 
subcellular destinations in the cell. The vast majority of SAP97 in the brain is of the β-
isoform and localize to perisynaptic regions outside the PSD while PSD-95 predominantly 
exists in the α-isoform localizing to the PSD. The α- and β-isoforms also influence the 
AMPA receptor mediated synaptic strength differently. The α-isoform regulates the synaptic 
insertion of AMPA receptors during basal activity, in the absence of NMDA receptor induced 
activity, whereas β-isoforms participate in activity-induced potentiation of the synaptic 
strength through CaMKII regulated insertion of AMPA receptors at the synapse (Schlüter et 
al., 2006). During basal activity palmitoylation of PSD-95 N-terminal cysteines in the α-
isoform leads to membrane insertion of the protein and concomitant surface expression of 
AMPA receptors. An increase in the synaptic activity and the rise in intracellular Ca2+ levels 
through NMDA receptor channels on the other hand activate Ca2+/calmodulin (CaM) that 
bind to the N-terminus of PSD-95 preventing its palmitoylation and leading to decreased 
surface expression of AMPA receptors through PSD-95 (Topinka and Bredt, 1998; El-
Husseini et al., 2002; Noritake et al., 2009; Zhang et al., 2014). As PSD-95 does not bind 
AMPA receptors directly the effect of PSD-95 on AMPA receptor surface expression is 
likely mediated through SAP97 or TARPs able of binding both PSD-95 and AMPA receptors 
simultaneously (Leonard et al., 1998; Cai et al., 2006; bChetkovich et al., 2002; Schnell et al., 
2002). Elevated intracellular Ca2+ also activates CaMKII, which has been shown to 
phosphorylate a serine residue (S39) in the N-terminal L27 domain of SAP97 driving SAP97 
to spines (Mauceri et al., 2004). This modification might explain how SAP97, which 
predominantly exists in the β-isoform containing the L27 domain and lacking C-terminal 
cysteines, can potentiate the synaptic strength during NMDA receptor induced activity by 
inserting GluA1 containing AMPA receptors at the synapse.   
 
1.3.4.2 SAP97 in GluA1 trafficking 
To exert their function GluA1 receptors need to reach their destination at the synapse. 
Through a series of regulated steps each likely involving interacting proteins (and post-
translational modifications), the newly formed receptors are transported from the ER via 
Golgi complex to the vicinity of the plasma membrane at spines waiting to be inserted in the 
perisynaptic membrane in response to synaptic activity (Sans et al., 2001; Rumbaugh et al., 
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2003; Nakagawa et al., 2004; Waites et al., 2009). SAP97 is reported to bind GluA1 early in 
the biosynthetic pathway and participate in the forward trafficking of GluA1 subunit 
containing receptors to the dendritic spines (Sans et al., 2001). 
 
Both the NMDA receptor activity-induced insertion of GluA1 containing AMPA receptors 
into the synapse, as well as basal AMPA receptor re-cycling, involve an actin-based motor 
protein myosin VI interacting with GluA1 receptors via SAP97. It has been shown, in 
hippocampal neurons, that inhibiting the interaction between the N-terminus of SAP97 
containing the L27 domain and the cargo domain of myosin VI causes a notable decrease in 
the number of synapses and a reduction in the number of surface exposed synaptic GluA1 
AMPA receptors. Moreover, inhibiting the SAP97-myosin VI interaction also negatively 
influences the increase in miniature excitatory postsynaptic currents generally associated with 
recruitment of AMPA receptors to the cell surface (Nash et al., 2010). Transport of GluA1 
containing AMPA receptors within the cell could also occur along microtubules mediated by 
motor proteins from the kinesin superfamily, via a SAP97 interaction. SAP97 in the brain can 
interact directly with kinesin KIF1Bα through PDZ interactions (Mok et al., 2002). 
 
GluA1 interacts via SAP97 also with A-kinase anchoring protein (AKAP79/150), a 
scaffolding protein for signaling proteins PKA, PKC and calcineurin (also called 
Ca2+/calmodulin dependent protein phosphatase 2B, PP2B). In response to LTP induction, 
AKAP79/150 is palmitoylated at two N-terminal cysteine residues and recruited to dendritic 
spines with a subsequent increase in surface expressed GluA1 receptors (Keith et al., 2012). 
Once at the synaptic surface, the activity of the GluA1 receptors can be modulated by 
phosphorylation/ dephosphorylation through signaling proteins bound to AKAP79/150 to 
regulate receptor activity and re-cycling.   
 
1.3.4.3 SAP97 in synaptogenesis  
The importance of SAP97 (and PSD-95) in the maturation of synapses has been 
demonstrated, by overexpressing SAP97 (or PSD-95) in mammalian synapses (El-Husseini et 
al., 2000; Nikonenko et al., 2008; Poglia et al., 2011). Overexpression of SAP97 in rat 
hippocampal pyramidal neurons increases the spine volume by threefold compared to the 
control spines. The size of PSDs also significantly increases within the spines, on an average, 
by 7.5-fold. In addition, overexpression of SAP97 promotes the formation of multi-
innervated spines (MIS) that is, single spines with synaptic contacts to multiple axons. 
Moreover, SAP97 also induces the formation of multiple excitatory synapses directly on 
dendritic shafts. Similar changes can be observed in hippocampal pyramidal neurons, which 
overexpress PSD-95 albeit in a lesser degree. Intriguingly, both the formation of MIS and 
dendritic shaft synapses is blocked by the NOS inhibitor L-NG-nitro arginine methyl ester 
(L-NAME). Additionally, SAP97 overexpression results in recruitment of nNOS (and PSD-
95) to synapses suggesting the morphological changes on the synapses are mediated by NO 
signaling via SAP97 and PSD-95. The ability of SAP97 to influence spine morphology 
through NO signaling has been implied to occur through a ternary complex were SAP97 
binds nNOS via PSD-95 (Nikonenko et al., 2008; Poglia et al., 2011). However, SAP97 is 
able to interact with nNOS also directly (Chang et al., 2011 and this study, III). One 
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distinguishing feature seen only when overexpressing SAP97, but not PSD-95, is the 
enwrapping and engulfing of the presynaptic terminals (Poglia et al., 2011). A possible 
explanation for this is the difference in the subcellular localization of SAP97 and PSD-95. 
While PSD-95 localizes evenly in the spine, clearly present in the PSD as well as in 
cytoplasmic compartments, SAP97 concentrates perisynaptically, at the edges of PSD 
(DeGiorgis et al., 2006; Waites et al., 2009). The preferential localization of SAP97 along the 
edges of the PSD, rather than within the PSD like PSD-95, could also explain the larger PSDs 
observed during SAP97 overexpression as compared to PSD-95 overexpression (Nikonenko 
et al., 2008; Poglia et al., 2011).  
 
SAP97 can also affect the development of the presynaptic neuron. Unlike the other DLGs, 
which predominantly have a postsynaptic, dendritic localization, SAP97 is also present in 
axons. It has been demonstrated in developing neurites of mice that SAP97, through a PDZ 
interaction with the somatostatin receptor subtype 1, participates in the axonal growth cone 
formation (Cai et al., 2008). The effects of SAP97 on the presynaptic neuron is not only 
restricted to presynaptically expressed SAP97. Postsynaptic overexpression of SAP97 has 
been reported to increase the size of the active zone and accumulation of presynaptic proteins 
through an unknown retrograde signaling event. This presynaptic effect is critically 
dependent on the PDZ domains, and to a lesser extent, the L27 and GUK domains of SAP97. 
More specifically, the effect of SAP97 overexpression on presynaptic growth requires 
simultaneous binding of yet unidentified ligand(s) to the first and second PDZ domains of 
SAP97. This presynaptic growth promoting effect can also be demonstrated by 
overexpressing PSD-95 or SAP102, although the effect is significantly more modest than 
with SAP97 (Regalado et al., 2006). The difference may be related to the unique features of 
SAP97: the N-terminal insertions between the L27 domain and the first PDZ domain (Lue et 
al., 1994; McLaughlin et al., 2002) and the I3 insertion in the Hook region (Lue et al., 1994). 
Especially the I3 insertion might be relevant, since it binds protein 4.1 granting 
multimolecular complexes of SAP97 access to postsynaptic surface from where it may 
promote presynaptic growth more effectively than the other DLGs (Rumbaugh et al., 2003). 
 
1.3.4.4 SAP97 and GluA1 in dendrite branching 
In the light of research results from several research groups highlighting the importance of 
SAP97 in GluA1 trafficking it was rather surprising when Zhou and co-workers reported in 
2008 that SAP97 had no discernible influence on GluA1 trafficking and cell surface 
association. Instead, their experiments showed that GluA1, through its C-terminal PDZ motif, 
is essential for bringing SAP97 to the plasma membrane, where SAP97 is able to translate the 
activity of GluA1 receptors into dendrite growth. The interaction is critically dependent on 
the second PDZ domain of SAP97, as a mutation disrupting the PDZ binding site of PDZ2 
abolishes the ability of GluA1 to chaperone SAP97 to the cell surface. For the growth 
promoting effect to take place at the plasma membrane GluA1 and SAP97 no longer need to 
be physically linked through a PDZ interaction. How SAP97 is able to control GluA1-
dependent dendrite growth is suggested to take place through a locally produced and 
diffusible messenger that signals from activated GluA1 receptors to SAP97 (Zhou et al., 
2008). Subsequent work on the growth promoting effects of SAP97 on dendrites following 
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GluA1 receptor activation have revealed that ligands to PDZ1, PDZ2, I3 and especially 
PDZ3, when localized at the plasma membrane, contribute to the dendrite growth (Zhang et 
al., 2015). The growth promoting effect of SAP97 and GluA1 on dendrites is synergistic, and 
is expressed at several levels including dendritic branching, size of the dendritic arbor, and 
dendritic length (Zhou et al., 2008; Zhang et al, 2015). SAP97 alone at the plasma membrane, 
in the absence of GluA1, is not able to promote dendrite growth, and it has been suggested 
that calcium influx through calcium permeable GluA1 channels drives the dendritic growth 
(Jeong et al., 2006; Zhang et al., 2015). 
 
  
35 
 
2. AIMS OF THE STUDY 
 
The aim of the study was to gain information on the structural basis and regulation of the 
interaction between GluA1 and SAP97. This interaction has been implicated in AMPA 
receptor cellular trafficking, synaptic plasticity and neuronal development, and in various 
neuropathologies, and thus the results will contribute to our understanding on the molecular 
basis of these important processes. 
 
The specific aims of the study were: 
1. to gain detailed structural information on the selective interaction of GluA1 with 
SAP97 identifying important determinants  involved in the regulation of the 
interaction (Publications I and II) 
2. to study the role of C-terminal GluA1 residue C893 (Publications I, II and III) 
3. to study the sensitivity of GluA1 for post-translational modification by NO and to 
explore the possibility that GluA1 is physically linked to nitric oxide synthase via 
SAP97 (Publication III) 
 
 
  
36 
 
3. MATERIALS AND METHODS 
 
With the exception of size exclusion chromatography and glutathione S-transferase (GST) 
pull-down studies, the materials and methods used in this study have been described in detail 
in the original publications (I-III). Therefore, only a list of those methods is provided here.  
 
 
Method      Original publication 
_____________________________________________________________________ 
Biotin-switch assay (BSA)    III 
Buffer exchange     I 
Bacterial protein expression    I, II 
Bacterial protein expression –isotope labeled I 
Chemical shift assignment     I* 
Crystal structure determination    II*    
Immunoprecipitation/ Streptavidin-precipitation II, III 
Mammalian cell culture     II, III 
Mass spectrometry analysis    I 
Microplate binding assay    II 
NMR model building      I* 
NMR spectroscopy      I* 
Peptide binding assay     I 
Plasmid construction     I, II, III 
Preparation of CysNO    III 
Protein crystallization     II* 
Protein purification     I, II 
SDS-PAGE      I, II, III 
Transfection      II, III 
Western blotting     I, II, III 
_____________________________________________________________________ 
* Methods not utilized by the author of this thesis 
 
Size-exclusion chromatography (I) 
Purified wt SAP97PDZ2 and SAP97PDZ2 C378G were analyzed by size-exclusion 
chromatography. For the purpose, a Superose 12 HR 10/30 gel filtration column (GE 
Healthcare Life Sciences) was equilibrated in 10 mM Bis-Tris buffer, pH 6.5. Standard 
proteins (Blue Dextran 2000 and HMW gel filtration calibration kit [GE Healthcare Life 
Sciences],  aprotinin [Sigma]), wt SAP97PDZ2 in the presence or absence of 10-15 mM 
dithiothreitol (DTT) and SAP97PDZ2 C378G in absence of DTT, were run in an ÄKTA Fast 
protein liquid chromatography (FPLC) system (GE Healthcare Life Sciences) operating at 4 
°C. Samples and standard proteins were diluted to 1-10 mg/ml in the eluent (10 mM Bis-Tris 
buffer, pH 6.5). Elution was monitored by UV absorbance at 280 nm and peak fractions were 
analyzed on non-reducing SDS-PAGE gels. 
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Generation of DNA constructs for GST pull-down studies (unpublished) 
SAP97PDZ1-3/PSD-95PDZ1-3 and PSD-95PDZ1-3/SAP97PDZ1-3 chimeras were generated through 
overlap extension PCR (OE-PCR) first amplifying separately the N-terminus (comprising the 
entire PDZ1 sequence and the N-terminal part of PDZ2) and the C-terminus (comprising the 
C-terminal part of PDZ2 and the entire PDZ3 sequence) of each MAGUK using full-length 
PSD-95 and SAP97 plasmid constructs as templates. Appropriate primers were used to 
introduce complementary sequences to the PDZ2 region of the SAP97 and PSD-95 PCR 
products, which in the subsequent PCR reactions were mixed, annealed and used as templates 
to produce chimeric SAP97PDZ1-3/PSD-95PDZ1-3 and PSD-95PDZ1-3/SAP97PDZ1-3 PCR products. 
The OE-PCR primers for the PDZ2 region, which were used to produce chimeras SAP97PDZ1-
3/PSD-95PDZ1-3 and PSD-95PDZ1-3/SAP97PDZ1-3 contained a silent mutation introducing an 
XhoI site, for analytical reasons, not present in the wt SAP97 and PSD-95 PDZ1-3 segments. 
For expression of His-tagged proteins the chimeric PCR products were cloned into a T7 
promoter-containing pTFT74HIPMC NcoI-XbaI-treated vector as previously described in the 
construction of bacterial expression vectors encoding wt PDZ1-3 domain segments of SAP97 
and PSD-95 (Cai et al., 2002). The mutations C378G and G219C were introduced to 
SAP97PDZ1-3/PSD-95PDZ1-3 and PSD-95PDZ1-3/SAP97PDZ1-3 chimeras respectively through PCR 
by amplifying the N-terminus (comprising the entire PDZ1 sequence and the N-terminal part 
of PDZ2) with 3’ primers containing the desired point mutation (C378G or G219C) as well as 
a silent mutation generating the restriction site for XhoI. Full-length PSD-95 and SAP97 
plasmid constructs were used as templates. The resulting PCR products were cloned into 
NcoI-XhoI-treated SAP97PDZ1-3/PSD-95PDZ1-3 and PSD-95PDZ1-3/SAP97PDZ1-3 chimeras 
described above producing SAP97PDZ1-3 C378G/PSD-95PDZ1-3 and PSD-95PDZ1-3 G219C 
/SAP97PDZ1-3. The generation of a GST fusion protein of wt GluA1 CTD has been described 
previously (Cai et al., 2002). The correctness of the chimeric constructs were verified by 
analytical restriction digestions and sequencing.  
 
Bacterial expression of proteins for GST pull-down assay (unpublished) 
Recombinant proteins used in GST pull-down assays were produced in Escherichia coli (E. 
coli) strain BL21 (GST-tagged GluA1 CTD) or BL21(DE3)pLysS (His-tagged proteins) as 
follows: cultures from single bacterial colonies grown overnight in 2 ml of LB medium 
(containing 100 μg/ml ampicillin) were diluted 1:80 with fore mentioned medium and the 
growth was continued vigorously shaking at 37 °C for approximately 3 h until the culture 
reached an absorbance between 0.4-0.6 when measured at wavelength 600 nm. Thereafter, 
isopropyl-D-thio-β-galactopyranoside was added to a final concentration of 0.5 mM to induce 
protein expression for 3 h while the culture was incubated under continuous shaking at 37 °C. 
Induced cells were pelleted, suspended in TNE-buffer (containing 50 mM Tris-HCl pH 7.5, 
120 mM NaCl, 1.0 mM EDTA, 1% (w/v) Triton X-100, 1 mM phenylmethylsulfonyl fluoride 
(PMSF), 5-10 μg/ml aprotinin and 5-10 μg/ml leupeptin) and sonicated on ice with a tip 
sonicator. Insoluble cell debris was removed by centrifugation (13500 g for 10 min at 4 °C) 
and the supernatant containing recombinant fusion protein was used in GST pull-down 
assays.  
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GST pull-down assay (unpublished) 
Bacterial lysates containing expressed protein of PDZ1-3 domain segments of SAP97, PSD-
95 or chimeras SAP97/PSD-95, PSD-95/SAP97, SAP97 C378G/PSD-95 and PSD-95 
G219C/SAP97 were incubated with GST-tagged GluA1 CTD attached to glutathione-
sepharose beads overnight at 4 °C (with or without 10 mM DTT). The glutathione-sepharose 
beads were pelleted at 850 g for 1 min and washed three times with TNE-buffer (with or 
without 10 mM DTT) and once with PBS (with or without 10 mM DTT). The bound proteins 
were eluted in SDS sample buffer and analyzed by immunoblotting. Specific binding of His-
tagged proteins to GST-tagged GluA1 CTD was assessed with an anti-His primary antibody 
and an alkaline phosphatase conjugated secondary antibody. The blots were developed in a 
colorimetric reaction using 5-bromo-4-chloro-3-indolyl phosphate and nitroblue tetrazolium 
as substrate. 
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4. RESULTS AND DISCUSSION  
 
4.1 Biochemical and structural studies with GluA1 C-terminus and SAP97 PDZ 
domains (I and II)  
 
Within the DLG subfamily of MAGUKs SAP97 is the only member reported to bind AMPA 
receptor subunit GluA1 directly (Leonard et al., 1998; Cai et al., 2002; Zhou et al., 2008). 
This highly selective binding of GluA1 to SAP97, but not to the closely homologous PSD-93, 
PSD-95 or SAP102, is surprising considering the extent of sequence homology and the 
functional redundancy observed in several loss-of-function experiments showing that the 
DLGs are able to compensate for each other (Elias et al., 2006; Howard et al., 2010; Sun and 
Turrigiano, 2011). 
 
4.1.1 Selectivity of GluA1-PDZ binding (II, unpublished) 
Earlier studies on the GluA1-SAP97 interaction had shown that the interaction between 
GluA1 and SAP97 involves the second PDZ domain of SAP97 (SAP97PDZ2) and is critically 
dependent on the C-terminal class I PDZ binding motif (-A-T-G-L) in GluA1 (I, Figure 1b) 
(Cai et al., 2002). Other pulldown studies, however, proclaimed the GluA1-SAP97 
interaction to involve the first PDZ1 domain of SAP97 (SAP97PDZ1) instead (Mehta et al., 
2001; Gardoni et al., 2003). To resolve this discrepancy, we performed a complementary 
experiment by coating microtiter plate wells with His-tagged SAP97PDZ1, SAP97PDZ2 and 
SAP97PDZ3 domains expressed in an E. coli BL21(DE3)pLysS strain and purified by 
immobilized metal chelation affinity chromatography (IMAC). The binding of GST-tagged 
C-terminal GluA1 wt or PDZ binding motif mutant (L907A) 11-mer peptides expressed in E. 
coli strain BL21 and purified by GST-sepharose was determined by utilizing anti-GST-
horseradish peroxidase as a marker. The results confirmed that both SAP97PDZ1 and 
SAP97PDZ2 (but not SAP97PDZ3) are able to bind GluA1 through a classical PDZ interaction, 
although the strongest binding was observed between SAP97PDZ2 and GluA1 (II, Figure 2). 
This is not surprising, since it is known that PDZ1 and PDZ2 domains often share binding 
partners (Lim et al., 2002). Importantly, GluA1 point mutant L907A showed strongly reduced 
binding to both PDZ1 and PDZ2 domains (II, Figure 2), consistent with type I PDZ 
interaction.  
 
Mutations to the C-terminal -A-T-G-L PDZ binding motif of GluA1 had shown that the 
threonine at position P-2 and leucine at position P0, when mutated to alanine destroyed the 
interaction to SAP97, while mutations to alanine and glycine in positions P-3 and P-1 had no 
effect on the interaction (Cai et al., 2002). Residues in positions P-2 and P0 make contacts 
with SAP97PDZ2 residues in the carboxylate binding loop (-G-L-G-F-) and to the first residue 
in the αB helix (histidine) which are conserved in all class I PDZ domains (Doyle et al., 
1996) (I, Figure 2b; II, Figure 3). Thus, other residues differing between SAP97 and the 
other members of the DLG subfamily had to account for the selectivity of the interaction. To 
pinpoint the critical residues in SAP97PDZ2 contributing to the highly selective interaction to 
GluA1, His-tagged PDZ1-3 chimeras comprising parts from SAP97 and PSD-95 were 
constructed. We chose to work with PSD-95 since the PDZ2 domains of SAP97 and PSD-95 
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differ only in nine amino acid residues (Figure 14). The PDZ1 and PDZ3 domains were kept 
intact and the crossover point between SAP97 and PSD-95 was within the PDZ2 domain 
leaving three of the differences to the N-terminal side and six to the C-terminal side of the 
chimeras. SAP97PDZ1-3 and PSD-95PDZ1-3 wt and chimeric variants were expressed in E. coli 
strain BL21(DE3)pLysS and their binding to recombinant GST-tagged GluA1 CTD 
expressed in BL21 was assessed in a GST pull-down assay directly from crude cell lysates. 
The PSD-95PDZ1-3 wt and PSD-95PDZ1-3/SAP97PDZ1-3 chimera repeatedly failed to bind to 
GluA1 CTD while SAP97PDZ1-3 wt and SAP97PDZ1-3/PSD-95PDZ1-3 chimera bound avidly to 
GluA1 CTD (Figure 15a), indicating that the ability to bind to GluA1 is conferred by the 
three SAP97-specific residues present in the PDZ2 segment N-terminal from the crossover 
point. The three differences between SAP97 and PSD-95, include two which conserve the 
nature of the side chain (L371 and K364 in SAP97 and I212 and R205 in PSD-95, 
respectively), and one nonconservative difference, cysteine (C378) in SAP97 and glycine 
(G219) in PSD-95. A GST pull-down assay performed under reducing conditions with GST-
tagged GluA1 CTD, wt SAP97PDZ1-3 and wt PSD-95PDZ1-3 suggested that the interaction 
between GluA1 and SAP97 is stabilized by a disulfide bond, since the presence of reducing 
agent DTT throughout the GST pull-down assay was able to abolish the interaction between 
SAP97 and GluA1 almost completely (Figure 15b). The involvement of SAP97 cysteine 
C378 in the interaction with GluA1, suggested by the result of the GST pull-down under 
reducing conditions, was further studied by introducing cysteine-to-glycine (or glycine-to-
cysteine) point mutations to the existing SAP97PDZ1-3/PSD-95PDZ1-3 and PSD-95PDZ1-
3/SAP97PDZ1-3 chimeras. The new chimeras (SAP97PDZ1-3 C378G /PSD-95PDZ1-3 and PSD-
95PDZ1-3 G219C /SAP97PDZ1-3) were used in GST pull-down assays along with wt SAP97PDZ1-
3 and PSD-95PDZ1-3. While the SAP97PDZ1-3/PSD-95PDZ1-3 chimera (containing three SAP97 
PDZ2 specific residues C378, L371 and K364) had bound avidly to GluA1 (Figure 15a), the 
SAP97PDZ1-3 C378G /PSD-95PDZ1-3 chimera (containing two SAP97 PDZ2 specific residues 
L371 and K364) did not. The equivalent point mutation (G219C) to the PSD-95PDZ1-
3/SAP97PDZ1-3 chimera in turn, resulted in a protein with the ability to bind GluA1 indicating 
that C378 in SAP97 plays a dominant role in the interaction with GluA1 (Figure 15c). To 
study the interaction between GluA1 and SAP97, and the role of cysteines therein, in greater 
detail we pursued peptide binding assays, NMR spectroscopy and X-ray crystallography with 
purified SAP97PDZ2 domains and C-terminal GluA1 13- or 18-mer peptides (I, Figure 1c). 
 
Figure 14. PDZ2 (SAP97 and PSD-95) alignment showing amino acid residue differences in blue letters. 
Residues in the peptide binding pocket marked with red letters (Chen et al., 2008). Conserved residues in the 
carboxylate-binding loop and the N-terminal histidine in αB helix, making contact with the ultimate and 
antepenultimate amino acid residues of the ligand are marked yellow. The crossover point for the chimeric 
SAP97PDZ1-3 and PSD-95PDZ1-3 constructs is marked with a dotted line. 
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Figure 15. GST pull-downs of His-tagged SAP97PDZ1-3 and PSD-95PDZ1-3 wt and chimeric constructs. (A) 
Binding of wt SAP97PDZ1-3, wt PSD-95PDZ1-3, SAP97PDZ1-3/PSD-95PDZ1-3 and PSD-95PDZ1-3/SAP97PDZ1-3 to GST-
tagged GluA1 CTD. (B) The effect of reducing agent DTT on the binding of wt SAP97PDZ1-3 and PSD-95PDZ1-3 
to GST-tagged GluA1 CTD. (C) Binding of wt SAP97PDZ1-3, wt PSD-95PDZ1-3, SAP97PDZ1-3C378G/PSD-95PDZ1-3 
and PSD-95PDZ1-3G219C/SAP97PDZ1-3 to GST-tagged GluA1 CTD. 
 
4.1.2 Assessment of the oligomeric state of purified PDZ2 domains (I) 
Recombinant forms of C-terminally His-tagged SAP97PDZ2 and PSD-95PDZ2 were expressed 
in E. coli strain BL21(DE3)pLysS and purified with immobilized metal chelation affinity 
chromatography. When analyzed by SDS-PAGE under reducing conditions, SAP97PDZ 
migrated as two separate bands consisting of a major 12 kDa and a minor 24 kDa band. 
Under non-reducing conditions, omitting 2-mercaptoethanol in the sample preparation, the 24 
kDa band became more prominent. PSD-95PDZ2 on the other hand, migrated as a single 12 
kDa band both under reducing and non-reducing conditions (I, Figure 2a). Tryptic digests of 
the reduced and alkylated SAP97PDZ2 12 and 24 kDa bands were analyzed by mass 
spectrometry resulting in three major identical peptide peaks (see I for details) and both the 
12 and 24 kDa bands were recognized by an anti-His antibody in Western blotting. SAP97PDZ 
was studied also by gel filtration chromatography in the presence or absence of the reducing 
agent DTT. Under non-reducing conditions, SAP97PDZ2 eluted as two separate peaks while 
SAP97PDZ2 under reducing conditions eluted largely as a single peak (Figure 16). The results 
suggest that purified SAP97PDZ2 is a heterogeneous mix of monomers and dimers, stabilized 
by a disulfide bond. The disulfide bridge stabilizing the dimer is formed by the conserved 
cysteine C378 present in SAP97, but lacking in PSD-95 and the other members of the PSD-
MAGUK family (I, Figure 2b). The additional weak 35 and 50 kDa bands seen in the SDS-
PAGE are likely aggregates of SAP97PDZ2 resistant to SDS. Intriguingly, the PDZ2 domain of 
MAGUK protein MAGI1 (the second of six PDZ domains in the human MAGI1 sequence) 
contains a cysteine (C526) at the equivalent position as C378 in SAP97PDZ2. In MAGI1PDZ2 
C526 is involved in the formation of disulfide linked dimers with an upstream cysteine 
(C553) of another monomer (Charbonnier et al., 2008; Charbonnier et al., 2011). 
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Figure 16. Size exclusion chromatography of SAP97PDZ2 in the presence and absence of DTT. In the 
absence of the reducing agent DTT SAP97PDZ2 elutes as two separate, dimer (elution volume 15.1 ml) and 
monomer (elution volume 15.9 ml), peaks. Addition of DTT to the sample increases the size of the monomer 
peak. 
 
4.1.3. Peptide binding studies on GluA1-SAP97 interaction (I) 
To characterize the GluA1-SAP97 interaction, a peptide binding assay with biotinylated 18-
mer C-terminal GluA1 peptides (Bio-GluA118) and SAP97PDZ2 was performed. 96-well 
microtiter plates were coated with SAP97PDZ2 or with a SAP97NTD control protein and the 
binding of Bio-GluA118 was assessed with streptavidin-alkaline phosphatase conjugate and 
colorigenic substrate. A biotinylated 14-mer C-terminal peptide (Bio-GluN2A14) from the 
GluN2A subunit of the NMDA receptor, which is known to bind to the first and second PDZ 
domains of PSD-MAGUKs (Niethammer et al., 1996; Cai et al., 2002), was used as a positive 
control. The affinities assessed through the peptide binding assay were 5.98 ± 1.20 μM for 
Bio-GluA1 and 0.40 ± 0.05 μM for Bio-GluN2A (I, Figure 3a). In the presence of unlabeled 
GluA118 the binding between Bio-GluA118 and SAP97PDZ2 was strongly reduced, whereas 
unlabeled GluN2A14 had little effect on the Bio-GluA118 and SAP97PDZ2 binding. Similarly, 
the binding between Bio-GluN2A and SAP97PDZ2 was strongly inhibited in the presence of 
unlabeled GluN2A, while GluA118 reduced the binding only slightly. Moreover, DTT 
strongly reduced the Bio-GluA118 -SAP97PDZ2 binding, while the effect was only minute on 
the Bio-GluN2A -SAP97PDZ2 interaction (I, Figure 3b). Furthermore, the binding could also 
be inhibited by pre-treating SAP97PDZ2 with N-ethylmaleimide, a reagent that alkylates free 
thiol groups found in cysteines irreversibly (I, Figure 3c). The results of the peptide binding 
assays suggested, that besides the rather low-affinity binding mediated by the PDZ binding 
motif in GluA1 and SAP97PDZ2, a covalent disulfide bond formed between C893 in GluA1 
and C378 in SAP97. 
 
To confirm the results of the peptide binding assay, of a disulfide complex between the 
GluA1 peptide and SAP97PDZ2, we employed an electrophoretic approach. Equal amounts of 
Bio-GluA118 and SAP97PDZ2 or Bio-GluA118 and SAP97PDZ2 C378S point mutant were mixed 
and analyzed by SDS-PAGE run under reduced and nonreduced conditions. Blotting with 
alkaline-phosphatase conjugated streptavidin revealed a covalent SDS-resistant complex 
between Bio-GluA118 and SAP97PDZ2 under nonreducing conditions, which could not be 
detected with the SAP97PDZ2 C378S point mutant (I, Figure 3d). 
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4.1.4 NMR studies on the GluA1-SAP97 interaction (I) 
The purified SAP97PDZ2 had a strong tendency to form dimers in solution in particular upon 
prolonged storage at 4 °C and to prevent SAP97PDZ2 dimer formation NMR spectroscopy 
(with 13C/15N-enriched protein) was performed under reducing conditions (10 mM DTT). 
Upon peptide titration, chemical shift changes (indicative of ligand binding) were observed 
mainly in the peptide binding groove of SAP97PDZ2 and no differences were observed in 
SAP97PDZ2 chemical shifts when titrated with either 13-mer or 18-mer GluA1 peptides (I, 
Figure 4a). Of note, none of the nine residues that differ between SAP97PDZ2 and PSD-95PDZ2 
resides in the peptide binding groove. Of the nine residues differing between SAP97PDZ2 and 
PSD-95PDZ2 (Figure 14), significant chemical shift changes were observed at three residues of 
SAP97PDZ2 which were all situated outside the peptide binding groove: L371 (corresponding 
to I212 in PSD-95PDZ2), T383 (M224) and T389 (A230). T383 is preceding the αB helix and 
situated next to the conserved H384 in the αB helix participating in all known class I PDZ 
interactions. The T389 resides on the αB helix, whereas L371 is situated on the βD strand on 
the surface, more than 8 Å away from the peptide. The equivalent chemical shift changes in 
T383 (M224) and T389 (A230) upon peptide binding are observed in the PSD-95PDZ2-nNOS 
complex as well (Wang et al, 2000). In the case of L371, the chemical shift change is 
probably due to structural rearrangement of the PDZ domain upon peptide binding, since the 
distance does not allow for a direct interaction with the peptide. 
 
In complementary experiments, SAP97PDZ2 (or PSD-95PDZ2) was titrated in a 13-mer GluA1 
peptide solution. Chemical shift changes were observed solely at the C-terminal part of the 
peptide (-A-T-G-L) with no significant differences between SAP97PDZ2 and PSD-95PDZ2. 
Thus, under reducing conditions, the C-terminal class I PDZ binding motif (-A-T-G-L) in 
GluA1 accounts solely for the binding, and the binding shows no selectivity between SAP97 
and PSD-95. These NMR studies indicate that under reducing conditions, GluA1 peptides 
bind equally to PDZ2 domains of SAP97 and PSD-95, suggesting that the selective (and 
apparently high-affinity) interaction seen between GluA1 and SAP97 in binding experiments 
with full-length molecules, could not derive simply through a canonical class I PDZ 
interaction involving only the last four GluA1 residues. 
 
As our earlier GST-pulldown experiments with chimeric PDZ domains and the plate binding 
assays with Bio-GluA118 peptides and SAP97PDZ2 suggested that the binding was strongly 
influenced by redox conditions, NMR experiments were also performed under non-reducing 
conditions. Titrations with GluA118 under non-reducing conditions resulted in a chemical 
shift in the 13Cβ atom of C378 from ~28 ppm to ~41 ppm indicating a change from reduced to 
oxidized form, i.e. demonstrating the formation of a disulfide-bridged complex. The 
formation of a covalent GluA1-SAP97 complex was further confirmed by mass spectrometry, 
which indicated that all SAP97PDZ2 protein was covalently bound to GluA118.  
 
4.1.5 A two-step binding model for the GluA1-SAP97 interaction (I) 
An increasing number of studies suggest that specificity and affinity of PDZ interactions are 
determined not only by the rather limited contacts between the extreme C-terminal PDZ 
binding motif and the canonical peptide binding groove, but that additional structures located 
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outside the region defining a classical PDZ interaction will add to the affinity and specificity 
of the interaction. This contribution of the sequence context can involve either extensions 
immediately preceding or following the PDZ binding motif or the PDZ domain, or 
alternatively protein interaction domains and regions situated further away from the region 
can strengthen the canonical PDZ interaction (Wang et al., 2010; Luck et al., 2012).  
 
Based on our peptide binding studies and NMR data a structural model of the SAP97PDZ2-
GluA118 interaction was built showing, at least in theory, that there were no structural 
constraints for simultaneous occupation of the peptide binding groove of PDZ2 by GluA1 C-
terminus and formation of a disulfide between C893 in GluA1 and C378 in SAP97 (I, Figure 
5b). Such dual occupancy would present additional specificity to the (apparently) low affinity 
interaction between the peptide binding groove of PDZ2 of SAP97 (and PSD-95) and the 
ultimate C-terminus of GluA1. However, judged from the chemical shifts of SAP97PDZ2 in 
covalent complex with GluA118 only a small fraction of the C-terminus of covalently bound 
peptide is occupying the peptide binding groove at any given time. To reconcile these 
observations, we suggest a two-step binding mechanism for the interaction: an initial low 
affinity interaction involving the canonical peptide binding groove of the PDZ2 domain and 
the ultimate C-terminal PDZ binding motif in GluA1 would position the interacting 
molecules in a favorable way to facilitate, in the second step, disulfide bridge formation 
between the interacting proteins (I, Figure 7a). Once the covalent bond is formed, the binding 
would become independent of the canonical PDZ interaction. Interestingly, the peptide 
titration experiments indicated that the upstream tripeptide –S-S-G- sequence in GluA1, 
found earlier to participate in the GluA1-SAP97 binding (Cai et al., 2002), was not involved 
in the chemical shift changes in SAP97PDZ2 induced by the peptide. It is thus likely that the –
S-S-G- sequence does not participate directly in the interaction with SAP97PDZ2, but may 
rather introduce structural flexibility to the C-terminus of GluA1 needed to establish stable 
binding via the proposed two-step mechanism. 
 
In order to analyze the potential physiological relevance of SAP97-GluA1 complexes 
stabilized by a disulfide bond, we studied whether the electrophoretic size of native SAP97 
and GluA1 is affected by non-reducing conditions. SDS-PAGE run under non-reducing 
conditions of GluA1 and SAP97 in detergent extracts of rat brain produced high-molecular 
weight complexes, including a 250-kDa species seen in both SAP97 and GluA1 
immunoblots, providing indirect support for the proposed model of a disulfide-linked GluA1-
SAP97 complex forming in native tissue (I, Supporting Figure 1). 
 
4.1.6 X-ray studies on SAP97PDZ2 (II) 
To study the structural details of the GluA1-SAP97 interaction further, we pursued X-ray 
crystallography and set up crystallization screens with SAP97PDZ2 and 18-mer GluA1 C-
terminal peptides. Due to the tendency of SAP97PDZ2 to form disulfide-linked dimers through 
C378 (see above, 4.1.2), we constructed variants of SAP97PDZ2 in which the C378 was 
replaced by either glycine (C378G) (the corresponding amino acid in the homologous PSD-
95PDZ2 and devoid of side chain) or serine (C378S) (differs from cysteine in one single atom, 
-SH in cysteine, and -OH in serine). Unlike the wild-type PDZ2, the C378 mutants had no 
45 
 
tendency to dimerize. The variants were expressed, purified and included in the crystal 
screens. Well-diffracting crystals were obtained both for free (SAP97PDZ2 C378G [2.44 Å 
resolution] and SAP97PDZ2 C378S [1.8 Å resolution]) and ligand bound SAP97PDZ2 (wt 
SAP97PDZ2 + GluA118 [2.35 Å resolution] and SAP97PDZ2 C378G + GluA118 [2.2 Å 
resolution]). The crystal structures obtained for SAP97PDZ2 were at the time the first SAP97 
PDZ2 structures to be solved both in its liganded and apo form. The crystal structure of 
SAP97PDZ2 was similar to other previously solved PDZ structures, containing 2 α-helices and 
6 β-strands folding into a typical compact globular protein interacting domain (Doyle et al., 
1996). The glycine and serine residues replacing the C378 in the SAP97PDZ2 variants reside 
on the outer surface and the side chain of serine points outwards into the solution (II, Figure 
4 and 5).  
 
4.1.6.1 Comparison of SAP97PDZ2 crystal to closely related PDZ structures (II) 
SAP97PDZ2 C378S and closely related SAP102PDZ2 and PSD-95PDZ2 in their apo forms were 
superposed to compare their structures. The backbone structures show high similarity with 
minor differences only in two loop areas extending from either side of the βB strand that 
forms one side of the peptide binding groove: βA- βB and βB- βC (II, Figure 5). In 
SAP97PDZ2 C378S, the βA- βB loop is closer to the αB helix, which forms the other side of 
the peptide binding groove, than in PSD-95 or SAP102. In addition, the βB- βC loop is bent 
closer to the C-terminus in PSD-95PDZ2, while it points outwards to the solution in SAP97PDZ2 
C378S and SAP102PDZ2. Differences observed in the loop areas of both βA- βB and βB- βC 
have been shown to add specificity and affinity to the canonical PDZ interaction involving 
the last four ligand residues and the peptide binding groove (Chi et al., 2009; Luck et al., 
2012). 
 
4.1.6.2 The ligand bound structure of SAP97PDZ2 (II) 
Well diffracting crystals in complex with a GluA118 peptide ligand were attained for both 
SAP97PDZ2 wt and the C378G variant. In both wild-type and C378G complexes, only the last 
four C-terminal residues (-A-T-G-L) of the ligand are seen in the crystal structure. The 
peptide is situated in the peptide binding groove between the βB strand and αB helix of the 
PDZ and antiparallel with the βB strand. The ultimate C-terminal residue L907, at position 
P0, docks the peptide in the peptide binding groove through hydrogen bonds between its 
carboxylate group and main chain amide nitrogens of L329, G330 and F331 of the 
carboxylate binding loop. An additional hydrogen bond is seen between the side chain of 
T905 at position P-2 of GluA1 and the conserved H384 at the N-terminal end of the αB-helix 
in SAP97PDZ2 (II, Figure 6). The interactions observed did thus not diverge beyond the 
canonical class I PDZ interaction seen in other known PDZ structures, and were consistent 
with the effects of point mutations reported earlier (Cai et al., 2002). The results from 
previous studies suggested that in addition to the four residues long C-terminal PDZ binding 
motif, -A-T-G-L, additional residues, -S-S-G- (at positions P-10 to P-8) (Cai et al., 2002) and 
the cysteine C893 at position P-14 (I) contribute to the interaction. However, in the crystal 
structure obtained with the 18-mer GluA1 ligand there was no electron density marking 
peptide binding to the PDZ domain beyond the last four residues and thus did not provide us 
with an answer to the high specificity and affinity interaction observed with intact molecules. 
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Regarding the SSG tripeptide, our NMR experiments (I) argued against its direct 
participation in binding and the crystallographic findings support this notion. The reasons for 
the notable absence of interactions beyond the very C-terminus from the crystal structure are 
currently unclear. It is possible that complexes, which include the inferred additional 
interactions, do not crystallize readily or are simply not formed under the conditions found 
optimal for the crystallization. Longer C-terminal peptides or even the entire CTD could 
result in more illuminating complex structures. However, the C-terminus of GluA1 like C-
terminal tails of other membrane proteins are predicted to be intrinsically disordered 
(Minezaki et al., 2007; Xue et al., 2009) and disordered proteins do not arrange into a stable 
fold but rather sample alternative conformations, which makes them hard to crystallize. A 
structurally disordered sequence in the C-terminal tail in close vicinity of a PDZ binding 
motif allows conformational freedom to search and connect with interacting partners 
(Magidovich et al., 2006). Thus the -S-S-G- sequence, containing disorder promoting amino 
acids serine and glycine (Williams et al., 2001; Romero et al., 2001), would not be required 
for the direct interaction between GluA1 and SAP97, but necessary in providing a flexible 
fold allowing perfect alignment of short sequences and residues involved in the high 
specificity and affinity binding. Moreover, our attempts to produce a longer C-terminal 
GluA1 domain suitable for crystallization screens have been unsuccessful due to the modest 
expression levels and poor stability of the purified recombinant GluA1 CTD. 
 
4.1.6.3 Conformational changes in SAP97PDZ2 upon peptide binding (II) 
While the wt SAP97PDZ2 crystals never diffracted without ligand, well-diffracting crystals 
were obtained from the C378G and C378S variants. By comparing the structures of ligand 
bound and free SAP97PDZ2, we discovered conformational changes taking place upon ligand 
binding. When a ligand is bound, the βA-βB loop (carboxylate binding loop) and αB-βF loop 
which are closest to the C-terminal end of the peptide move outwards away from each other. 
In the unliganded structure K324 preceding the -G-L-G-F- repeat in the βA-βB loop makes 
contact with D396 in the αB-βF loop. However, in the ligand-bound structure K324 moves to 
form hydrogen bonds to main chain and side chain oxygens in T394 and main chain oxygen 
in S395 (II, Figure 7). Such conformational change to better accommodate the peptide in the 
peptide binding groove had not been described previously for a PDZ-peptide interaction. 
Subsequent work by Chi and co-workers in 2009 with SAP97PDZ2 and a peptide of human 
papillomavirus type 18 protein E6 (HPV-18 E6) reported a similar conformational change 
and suggested that the interaction is an allosteric two-step mechanism, with an initial 
complex forming through a fast an unspecific association, which then undergoes a 
conformational change to lock the complex via an induced fit mechanism. The sequential 
mechanism allows the PDZ domain to screen a vast number of ligands and “lock” those with 
highest affinity and it was suggested that all peptides bind SAP97PDZ2 via the induced fit 
mechanism (Chi et al., 2009). However, such a mechanism is unlikely to have a strong 
contribution to the affinity and strict SAP97-selectivity of the GluA1 interaction, as the 
crystal structure of the complex does not reveal any direct interactions additional those 
involving the last four residues.  
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4.2 Functional role of C-terminal C893 of GluA1 (III) 
 
Previous work with synthetic GluA1 C-terminal peptides (I, II) identified C893 as a reactive 
residue capable of forming an intermolecular disulfide with C378 of SAP97PDZ2. To study the 
functional role of C893 in a more physiological context we in the next set of experiments 
chose to work with full-length GluA1 and SAP97 molecules.  
 
4.2.1 The contribution of C893 on GluA1-SAP97 interaction (III) 
To examine the contribution of C893 on SAP97 interaction with full-length molecules, 
GluA1 wt and the point mutant GluA1 C893S were co-expressed together with a recombinant 
biotin-tagged SAP97 (Bio-SAP97) in transiently transfected human embryonic kidney cells 
(HEK 293(T) cells). The cells were lysed and SAP97-GluA1 complexes were harvested 
through a streptavidin-sepharose pulldown assay and analyzed by western blotting. The 
results show that while GluA1 wt and GluA1 C893S both bind to SAP97, the mutation 
strongly reduces the binding (III, Figure 2c, d). This result with full-length molecules is 
consistent with the observations seen with short GluA1 peptides and individual PDZ2 
domains (I), that C893 is an important residue contributing, however not absolutely 
necessary, to the interaction with SAP97. Therefore, it is possible that a transient disulfide 
bond will form between GluA1 and SAP97 under suitable conditions, thereby increasing the 
amount of the complex that can be detected at any given time. However, the ability of GluA1 
C893S to form a complex with SAP97 that is stable enough to be isolated by streptavidin 
pulldown clearly indicates that disulfide- or C893- independent mechanisms are sufficient for 
the interaction to take place.  
 
4.2.2 The contribution of C893 on GluA1 protein expression (III) 
We noticed that a mutation to C893 also has an effect on the expression levels of receptor 
molecules in HEK 293 cells. Full-length GluA1 wt or GluA1 C893S were expressed either 
alone or co-expressed with SAP97, whereafter the GluA1 protein levels were quantified from 
western blot signals. The expression levels of GluA1 C893S were consistently two to three 
times higher than the GluA1 wt expression levels, and unaffected by co-expressed SAP97. 
The expression levels of GluA1 wt on the other hand experienced a roughly twofold increase 
when co-expressed with SAP97 (III, Figure 2a, b), in itself an indication of an interaction 
between the molecules. The results suggest that the loss of thiol function (i.e. cysteine to 
serine mutation) stabilizes the receptor in the absence of GluA1 ligand. On the other hand, 
the increased expression level of the wt receptor when co-expressed with SAP97 indicates 
that SAP97 is able to regulate GluA1 stability through an interaction involving C893. It is 
possible that GluA1 CTD residue C893 plays a supportive role in receptor turnover, and an 
interaction with SAP97 would shield the C893 in GluA1 thus making it inaccessible for 
posttranslational cysteine modifications or competing protein interactions which would lead 
to receptor degradation.  
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4.3 GluA1 as target for S-nitrosylation (III) 
 
Our earlier study with GluA1 18-mer peptides (I) revealed that C893 contains a reactive thiol 
which is able to form a disulfide with C378 in SAP97PDZ2 and is modified by alkylation. 
Thus, we wondered if the reactive C893 could also be a target for reversible post-translational 
thiol modifications. As many of the proteins, residing in the glutamatergic synapse have been 
shown to be sensitive to S-nitrosylation the effect of NO on GluA1 cysteines, and C893 
specifically, was studied in particular. 
 
Several GluA1 N- and C-terminal deletion mutants, as well as several short C-terminal 
domains of GluA1 with single C-terminal cysteine point mutations (targeting the three CTD 
cysteines separately) were made and their susceptibility to NO were assessed through the 
biotin switch assay (Jaffrey and Snyder, 2001). After subjecting the samples to S-
nitrosylation, in the first step of the assay the free thiols insensitive to NO are alkylated 
whereafter, the NO-modified thiols, i.e. nitrosothiols, are reduced to free thiols by ascorbate. 
In the last steps of the assay the thiol groups, marking originally S-nitrosylated cysteines, are 
biotinylated. Biotinylated proteins are then harvested with streptavidin-sepharose and 
analyzed on western blots. A signal on the western blot is an indication of the existence of S-
nitrosylated protein in the sample. 
 
Initially we determined the receptiveness of full-length GluA1 receptors to cell-permeable 
NO donor, S-nitrosocysteine (CysNO) in live HEK293 cells using the biotin switch assay. A 
positive signal was indeed observed using the assay and the result was confirmed by treating 
HEK293 cell lysates expressing full-length GluA1 or N- and C-terminal deletion mutants 
thereof with S-nitrosoglutathione (GSNO) another commonly used but cell-impermeant NO 
donor. Positive signals were observed not only for the full-length molecule, but also for the 
N- and C- terminal deletion mutants suggesting that several cysteines in different parts of the 
GluA1 receptor are sensitive to S-nitrosylation (III, Figure 4a, b, c). As our primary interest 
was in the three C-terminal cysteines of GluA1 including C893, we investigated the 
susceptibility of short C-terminal domains of wt and cysteine-to-serine point mutants, C829S, 
C843S and C893S to NO. Of the three C-terminal cysteines, only C893 was found to be 
sensitive for S-nitrosylation (III, Figure 4d), confirming the reactive nature of C893 and 
suggesting that GluA1 protein interactions might be redox-regulated by thiol modifications to 
C893. 
 
4.4 Association of SAP97 and GluA1 with nNOS (III) 
 
Intrigued by the finding that cysteine residues in GluA1 are indeed S-nitrosylated we 
wondered if GluA1 could associate with neuronal nitric oxide synthase (nNOS) analogous to 
the NMDA receptors. The NMDA receptors are functionally regulated by S-nitrosylation and 
physically linked to nNOS via PSD-95. The first and second PDZ domains of PSD-95 bind to 
the C-terminus of NMDA receptors through a classical type I PDZ interaction (Lim et al., 
2002). PSD-95 also interacts with nNOS through an unconventional PDZ-PDZ interaction 
(Brenman et al., 1996; Christopherson et al., 1999). NMDA receptor activity leads to an 
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elevated intracellular Ca2+ concentration and activation of nNOS via Ca2+/calmodulin. This 
leads to generation of NO and subsequent S-nitrosylation of cysteine residues in nearby 
proteins, including the extracellular portion of the NMDA receptor regulating the 
conductance through the receptor channel, especially during hypoxia, thus presenting a 
neuroprotective role for NO through S-nitrosylation (Lei et al., 1992; Choi et al, 2000; 
Takahashi et al., 2007). Furthermore, PSD-95 is also sensitive to S-nitrosylation. The C-
terminus of the major isoform of PSD-95 contains two conserved N-terminal cysteines C3 
and C5 that when palmitoylated stabilize membrane association of PSD-95 and interacting 
proteins. Ca2+ influx through NMDA receptor channels and the subsequent NO production 
results in S-nitrosylation of the C-terminal cysteines in PSD-95 counteracting the stabilizing 
effect of palmitoylation on PSD-95 membrane association. In this way, PSD-95 is able to 
regulate the signal transduction by reciprocal S-nitrosylation and palmitoylation of its N-
terminal cysteines (Ho et al., 2011).  
 
Recognizing several similarities between NMDA and GluA1 receptor types such as calcium-
permeability, NO sensitivity, and the association with a MAGUK protein, we sought to find 
out if SAP97 could bridge GluA1 to nNOS similar to PSD-95 in the ternary NMDA-PSD-95-
nNOS- complex. For this purpose, we first studied the interaction of recombinant biotin-
tagged SAP97 and PSD-95 with nNOS in a streptavidin-pulldown assay. Binary complexes 
were observed between nNOS and the positive control, PSD-95 (nNOS-PSD-95), but also 
between nNOS and SAP97 (nNOS-SAP97) (III, Figure 5a, b). The nNOS-SAP97 binary 
complex was also detected in immunoprecipitations of native brain tissue from postnatal day 
7 rat (III, Figure 5c), supporting its physiological relevance. Encouraged by the findings we 
examined the formation of a potential ternary complex GluA1-SAP97-nNOS. For this 
purpose we performed streptavidin-pulldowns from HEK293T cell lysates triply transfected 
with biotin-tagged nNOS, GluA1 and SAP97. GluA1 indeed co-precipitated with nNOS 
suggesting a ternary complex bridged by SAP97 in analogy with the NMDA-PSD-95 –
nNOS- complex, as no direct interaction was observed between nNOS and GluA1 (III, 
Figure 5d). Interestingly, in the absence of GluA1 we observed that the association between 
SAP97 and nNOS decreased, suggesting that GluA1 may promote SAP97-nNOS binding, 
possibly by inducing a conformational change in SAP97 upon binding to increase its binding 
affinity to nNOS. It has been shown, that a PSD-95 PDZ1-PDZ2 tandem construct, 90 % 
identical to the corresponding SAP97 segment, adopts different conformations depending on 
whether it is free or occupied by ligands. The ligand-free PSD-95 PDZ tandem is 
conformationally restrained, with parallel arrangement of peptide binding grooves. Upon 
ligand-binding, the flexibility of the short linker between PDZ1 and PDZ2 increases to allow 
for antiparallel ligand binding and increased ligand binding affinity (Figure 13) (Wang et al., 
2009). As both the PDZ1 and PDZ2 domains of SAP97 have been implicated in interactions 
with GluA1 (II) and nNOS (Chang et al., 2011), a similar rearrangement of the SAP97 
PDZ1-PDZ2 tandem is also likely to take place upon simultaneous binding of GluA1 and 
nNOS. 
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5. CONCLUDING REMARKS 
 
Since 1998, when the interaction between SAP97 and GluA1 was initially discovered by 
Leonard and co-workers, we have been presented with numerous studies indicating important 
roles for SAP97 in AMPA receptor trafficking, targeting and function as well as in neuronal 
development (Sans et al., 2001; Rumbaugh et al., 2003; Dell’Acqua et al., 2006; Schlüter et 
al., 2006; Zhou et al., 2008; Waites et al., 2009; Howard et al., 2010; Poglia et al., 2011; 
Zhang et al., 2015). The specific aims of this study was to gain insights on the structural basis 
and regulation of the specific interaction between SAP97 and GluA1, and for that purpose we 
pursued several biochemical (I, II, III) and structural studies (I, II).  
 
In our search for structural determinants accounting for the specific highly selective 
interaction between GluA1 and SAP97, it soon became evident that additional elements 
beyond the canonical type I PDZ interaction, i.e. the last four C-terminal residues in GluA1 
and the PDZ binding groove of the second PDZ domain in SAP97, must be involved. In 
addition to the low-affinity binding observed for the short peptide sequence (-A-T-G-L) in 
the peptide groove we identified C893 upstream the PDZ binding motif in the intracellular 
cytosolic tail of GluA1 and C378 situated on the surface of the second PDZ domain of 
SAP97 outside the peptide binding groove as reactive cysteines participating in the 
interaction through a covalent disulfide bond (I). There is accumulating evidence of the 
importance of extensions to the classical PDZ interaction in determining protein specificity 
and affinity. These extensions include upstream ligand residues beyond the PDZ binding 
motif and regions outside the peptide binding groove of the PDZ domain (Ye and Zhang, 
2013; Wang et al., 2009).  
 
Intracellular disulfide formation is considered relatively rare due to the reducing potential of 
the eukaryotic cytosol and traditionally protein oxidation has been regarded as an event 
linked almost solely to oxidative stress and pathological conditions. However, there is 
increasing evidence supporting the formation of cytosolic intra- and intermolecular disulfides 
and their redox regulation under normal physiological conditions, and cytosolic disulfide 
stabilized interactions have been reported for PDZ scaffolds as well (Kimple et al., 2001; van 
den Berk et al., 2005; Mishra et al., 2007; Liu et al., 2011).  
 
The crystal structure obtained of SAP97PDZ2 in complex with a GluA1 18-mer peptide shows 
a typical class I PDZ interaction similar to the structures of many other PDZ-peptide 
complexes. Disappointingly, only the last four residues of the GluA1 peptide are visible in 
the structure, including the hydrogen bonds between the C-terminal peptide residue L907 
(position P0) and the residues L329, G330, and F331 in the conserved carboxylate binding 
loop, as well as a hydrogen bond between the peptide residue T905 (position P-2) and the 
conserved H384 in the αB helix (II). As there was no discernible electron density for bound 
peptide beyond the last four residues of peptide the crystal structure did not provide an 
explanation for the contribution of upstream elements (C893, -S-S-G- sequence) to SAP97 
binding (I). The plausible reason for the lack of electron density for the C-terminal residues 
extending beyond the PDZ binding motif is that the C-terminus of GluA1 is predicted to be 
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disordered (Minezaki et al., 2007; Xue et al., 2009) and thus do not arrange into a stable fold 
which makes it hard to crystallize.  
 
A novel observation from the crystals in their liganded and apo form was the structural 
changes taking place in two loop areas, βA-βB loop and αB-βF, upon peptide binding. 
Peptide binding leads to a slight opening of the binding groove to better facilitate peptide 
binding in the cavity (II).  
 
In addition to its role in a direct interaction with SAP97 (I, III) the thiol group of GluA1 
C893 was shown to be a target for reversible post-translational S-nitrosylation (III). 
Moreover, we discovered that GluA1 is physically linked to nNOS via SAP97 in vitro (III). 
The thiol modifications, i.e. the intermolecular disulfide and the post-translational S-
nitrosylation, are not mutually exclusive, rather one can envision that the thiol modifications 
can both take place and be transiently regulated depending on the cellular context. At the 
level of ER-Golgi, where the initial interaction between GluA1 and SAP97 has been reported 
to take place (Sans et al., 2001) the interaction with SAP97 can offer stability to the newly 
formed glutamate receptor through an intermolecular interaction involving C893. At the 
plasma membrane on the other hand the situation is different. Homomeric GluA1 receptors 
are, when activated through agonist binding, calcium-permeable. SAP97 binds to both GluA1 
and nNOS thus linking receptor activity directly to NO formation at the plasma membrane. 
Subsequent S-nitrosylation of C893 has been reported to lead to receptor endocytosis 
(Selvakumar et al., 2013), which might serve a protective role in neuronal cells. From our 
work it is not clear whether GluA1 and SAP97 can form disulfide linked complexes at the 
plasma membrane, which is the site where S-nitrosylation of GluA1 C893 is reported to take 
place. Further work with endogenous molecules is clearly warranted and will clarify the 
functional and physiological role of the reactive C893 in GluA1. 
 
Nevertheless, our work have identified C893 of GluA1 and C378 of SAP97 as reactive 
cysteines participating both in a direct interaction between the proteins and due to their 
reactive nature serving as targets for S-nitrosylation and possibly other post-translational thiol 
modifications such as palmitoylation, ubiquitination, S-glutathionylation to mention just a 
few. It is plausible that thiol modifications like S-nitrosylation, disulfide formation and others 
can regulate reactive cysteines (Hess and Stamler, 2012) although proteomic analysis of 
cysteine modifications of proteins suggest only modest overlapping of redox-dependent 
cysteine modifications (Gould et al., 2013). 
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